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Katie Myers Smith,1 Natalie Bisal,1 Jinshuo Li,3 Steve Parrott,3
Peter Sasieni,2 Lynne Dawkins,4 Louise Ross,5 Maciej Goniewicz,6
Qi Wu3 and Hayden J McRobbie1
1Health and Lifestyle Research Unit, Wolfson Institute of Preventive Medicine, Queen Mary
University of London, London, UK
2King’s Clinical Trials Unit, Institute of Psychiatry, King’s College London, London, UK
3Department of Health Sciences, University of York, York, UK
4Centre for Addictive Behaviours Research, School of Applied Sciences, London South Bank
University, London, UK
5Leicester City Council, Leicester, UK
6Department of Health Behavior, Division of Cancer Prevention and Population Sciences,
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
*Corresponding author a.phillips-waller@qmul.ac.uk
Background: Over the past few years, a large number of smokers in the UK have stopped smoking
with the help of e-cigarettes. So far, UK Stop Smoking Services (SSSs) have been reluctant to include
e-cigarettes among their treatment options because data on their efficacy compared with the licensed
medications are lacking.
Objective: The objective was to compare the efficacy of refillable e-cigarettes and nicotine replacement
therapy (NRT) products, when accompanied by weekly behavioural support.
Design: A randomised controlled trial comparing e-cigarettes and NRT.
Setting: Three sites that provide local SSSs.
Participants: The participants were 886 smokers seeking help to quit smoking, aged ≥ 18 years, not
pregnant or breastfeeding, with no strong preference to use or not to use NRT or e-cigarettes in their
quit attempt, and currently not using NRT or e-cigarettes. A total of 886 participants were randomised but
two died during the study (one in each study arm) and were not included in the analysis.
Interventions: The NRT arm (n = 446) received NRT of their choice (single or combination), provided for up
to 12 weeks. The e-cigarette arm (n = 438) received an e-cigarette starter pack and were encouraged to buy
addtional e-liquids and e-cigarette products of their choice. Both arms received the same standard behavioural
support. Participants attended weekly sessions at their SSS and provided outcome data at 4 weeks. They were
then followed up by telephone at 6 and 12 months. Participants reporting abstinence or at least 50% reduction
in cigarette consumption at 12 months were invited to attend for carbon monoxide (CO) validation. Participants/
researchers could not be blinded to the intervention.
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Main outcome measures: The primary outcome was CO-validated sustained abstinence rates at 52 weeks.
Participants lost to follow-up or not providing biochemical validation were included as non-abstainers. Secondary
outcomes included abstinence at other time points, reduction in smoke intake, treatment adherence and
ratings, elicited adverse reactions, and changes in self-reported respiratory health. A cost-efficacy analysis of
the intervention was also conducted.
Results: The 1-year quit rate was 9.9% in the NRT arm and 18.0% in the e-cigarette arm (risk ratio 1.83,
95% confidence interval 1.30 to 2.58; p < 0.001). The e-cigarette arm had significantly higher validated
quit rates at all time points. Participants in the e-cigarette arm showed significantly better adherence and
experienced fewer urges to smoke throughout the initial 4 weeks of their quit attempt than those in the
NRT arm, and gave their allocated product more favourable ratings. They were also more likely to be still
using their allocated product at 1 year (39.5% vs. 4.3%, χ2 = 161.4; p < 0.001). Participants assigned
to e-cigarettes reported significantly less coughing and phlegm at 1 year than those assigned to NRT
(controlling for smoking status). A detailed economic analysis confirmed that, because e-cigarettes incur
lower NHS costs than NRT and generate a higher quit rate, e-cigarette use is more cost-effective.
Limitations: The results may not be generalisable to other types of smokers or settings, or to cartridge-based
e-cigarettes.
Conclusions: Within the context of multisession treatment for smokers seeking help, e-cigarettes were
significantly more effective than NRT. If SSSs provide e-cigarette starter packs, it is likely to boost their
success rates and improve their cost-efficacy.
Future work: The efficacy of e-cigarettes provided with different levels of support will show whether
smokers should be encouraged to switch to vaping within support services or whether e-cigarettes can be
recommended with less intensive or no support.
Trial registration: Current Controlled Trials ISRCTN60477608.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 43.
See the NIHR Journals Library website for further project information. The trial was supported by the
Cancer Research UK Prevention Trials Unit (grant A16893).
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Plain English summary
A large number of smokers in the UK have stopped smoking with the help of e-cigarettes, but it is notknown if e-cigarettes are as helpful as stop smoking medications that are provided by the UK Stop
Smoking Services (SSSs). This information is needed to decide whether or not SSSs should include
e-cigarettes among their treatment options.
A total of 886 smokers who were seeking help with quitting and did not mind whether they would use
nicotine replacement therapy (NRT), such as nicotine patches, or e-cigarettes were recruited at three SSSs.
The smokers were randomly allocated (by chance) to receive weekly behavioural support and either a NRT of
their choice (a single NRT product or product combinations) (n = 447) or a starter pack of e-cigarettes (n = 439).
The trial ran from May 2015 to February 2018.
The participants were followed up for 1 year to see how many stopped smoking in each group.
Smokers using e-cigarettes suffered less cigarette withdrawal discomfort early on and had higher quit rates
at all time points. At 1 year, 10% of participants in the NRT trial arm had been abstinent for the whole year,
compared with 18% in the e-cigarette arm; regarding abstinence for at least 6 months, the figures were
12% in the NRT arm and 21% in the e-cigarette arm. Of interest, coughs and phlegm production also
reduced more in people quitting with e-cigarettes than those quitting with NRT. This supports previous
reports suggesting that an ingredient in e-cigarettes (i.e. propylene glycol) may protect vapers from airborne
infections.
E-cigarette starter packs cost much less than NRT and so, if SSSs provide them, their use is likely to boost
the success rates and reduce the costs of SSSs.
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Scientific summary
Background
UK Stop Smoking Services (SSSs) provide a combination of behavioural support and licensed stop smoking
medications. Over the past few years, a large number of smokers in the UK have stopped smoking with
the help of e-cigarettes. So far, SSSs have been reluctant to include e-cigarettes among their treatment
options because data on their efficacy compared with licensed medications are lacking.
Design
This was a randomised controlled trial comparing e-cigarettes with nicotine replacement therapy (NRT).
Setting
The setting comprised three sites that provide local SSSs.
Participants
The participants were 886 smokers seeking help, who were aged ≥ 18 years, not pregnant or breastfeeding,
had no strong preference to use or not to use NRT or e-cigarettes in their quit attempt and were currently
not using NRT or e-cigarettes.
Interventions
The NRT arm received NRT of their choice (single or combination), provided for up to 12 weeks. The e-cigarette
arm received an e-cigarette starter pack and were encouraged to buy additional e-liquids and e-cigarette
products of their choice. Both arms received the same standard behavioural support. Participants attended
weekly sessions at their SSS, as per standard practice, and provided outcome data at 4 weeks. They were
then followed up by telephone at 6 and 12 months. Participants reporting abstinence or at least a 50%
reduction in smoking at 12 months were invited to attend for carbon monoxide (CO) validation.
Main outcome measures
The primary outcome was CO-validated sustained abstinence rates at 52 weeks post target quit date. Several
sensitivity analyses were also prespecified. Participants lost to follow-up or not providing biochemical validation
were included as non-abstainers. Secondary outcomes included CO-validated sustained abstinence rates
between 26 and 52 weeks, abstinence rates at previous time points [4 weeks (CO validated) and 26 weeks
(self-report)], CO-validated reduction in smoking and smoke intake of ≥ 50%, and treatment adherence and
ratings. A cost-efficacy analysis of the intervention was also conducted.
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Results
Clear differences between the two trial arms emerged early on. Participants in the e-cigarette arm showed
significantly better adherence and experienced fewer urges to smoke throughout the initial 4 weeks of
their quit attempt than those in the NRT arm, and gave their allocated product more favourable ratings.
The e-cigarette arm had significantly higher validated quit rates at all time points. Regarding the primary
outcome, sustained biochemically validated 1-year quit rate with NRT was 10%, which corresponds with
success rates reported previously for the UK SSSs. In the e-cigarette arm, the quit rate was 18% (risk ratio
1.83, 95% confidence interval 1.30 to 2.59; p < 0.001). Participants assigned to e-cigarettes reported
significantly less coughing and phlegm at 1 year than those assigned to NRT. A detailed economic analysis
confirmed that, because e-cigarettes incur lower NHS costs than NRT and generate a higher quit rate,
e-cigarette use is more cost-effective.
Conclusions
Within the context of multisession treatment for smokers seeking help, e-cigarettes were significantly more
effective than NRT. If SSSs provide e-cigarette starter packs, it will boost their success rates and improve
the cost-efficacy and probably also the attractiveness of their service.
Limitations
E-cigarettes are popular and easily accessible. Participants in the NRT arm were more likely to switch to
e-cigarettes than participants in the e-cigarette arm were to switch to NRT. However, this could be expected
to bias the results towards the null hypothesis. The control intervention included NRT combinations and so it
was not possible to compare e-cigarettes with a single NRT, but, as NRT combinations are more effective
than a single NRT, this too makes the trial more conservative. The trial results apply to settings in which
smokers can freely select the types of e-cigarettes and e-liquids that they like, namely real-life usage, but
may not be generalisable to providing just a single e-cigarette product to all.
Trial registration
This trial is registered as ISRCTN60477608.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. The trial was supported by the Cancer Research UK Prevention Trials Unit
(grant A16893).
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Chapter 1 Introduction
E -cigarettes are a popular option for smokers seeking to limit the health risks of smoking.
1 E-cigarettes
are unlikely to be harmless, but the risk of their use has been estimated to be < 5% of the risks of
smoking.2,3 No health risks were identified over some 18 months of use,4 and there is some evidence that
smokers who successfully switch to vaping reduce their nicotine dependence and often stop vaping as
well. For example, in the UK, there are currently some 1.5 million ex-smokers who have stopped smoking
with the help of e-cigarettes, of whom some 700,000 have stopped vaping as well.5
Current smoking cessation treatments provide a combination of behavioural support and medications that
target cigarette withdrawal discomfort,6 but sensorimotor factors that accompany smoking and that are likely
to be reinforcing for smokers are not well addressed.7 E-cigarettes pose a promise to fill this gap, and some
UK Stop Smoking Services (SSSs) are now including e-cigarettes in their routine work. However, data on
e-cigarette efficacy in this context are limited. Information is needed on whether or not e-cigarettes can
match or even surpass the efficacy of other evidence-based treatments that are currently used. The question
is particularly important because e-cigarettes are much less expensive than stop smoking medications and
smokers are purchasing e-cigarettes themselves, which means that their use represents no cost to health-care
systems. In addition, they hold a greater appeal to smokers and are used more widely than licensed stop
smoking medication,8 which suggests that they could potentially have a bigger population impact.
Only three randomised controlled trials (RCTs) have evaluated the efficacy of e-cigarettes when offered
proactively by health professionals as a stop smoking treatment. A Cochrane meta-analysis4 of two trials that
provided long-term outcomes9,10 (both trials used early e-cigarette models with poor nicotine delivery) found
evidence that e-cigarettes containing nicotine are more likely to help smokers quit than placebo e-cigarettes
with one trial showing the same (low) effect for e-cigarettes and for nicotine patches.9 The third trial11 had
only a 2-month outcome and so was not included in the meta-analysis, but it showed a significant effect
of a more advanced (second-generation) e-cigarette product. Another trial12 was published in 2018, but its
rationale was unclear and is difficult to interpret. Participants had access to cartridge-based e-cigarettes in
both trial arms, but one arm was also given stop smoking medications. In addition, treatments were offered
to people who did not ask to be treated and, to be classified as an abstainer, participants had to undergo
repeated blood sampling. ‘Abstinence rates’ were thus extremely low (1% in the arm allocated e-cigarettes
only and 0.5% in the arm allocated medication plus e-cigarettes). The trial12 also evaluated incentives.
Paying abstainers US$600 to attend the blood sampling increased ‘abstinence rates’ only to 2.9%.12
The present trial was set up to evaluate the efficacy of a refillable e-cigarettes compared with the efficacy of
nicotine replacement therapy (NRT) products as currently used routinely by SSSs, when accompanied by
weekly behavioural support (as provided routinely by the services). In routine use, NRTs are included as a single
product of the patient’s choice, selected from among a number of available options, or in combinations,
depending on a patient’s preferences.
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Chapter 2 Methods
Some parts of this chapter are from The New England Journal of Medicine, Hajek P, et al.
13 A randomized
trial of e-cigarettes versus nicotine-replacement therapy, Vol. 380, pp. 629–37. Copyright © 2019
Massachusetts Medical Society. Reprinted with permission.
Overview of trial design
This was a pragmatic RCT conducted between 2015 and 2018 in three sites in England that provide local
SSSs. Eligible smokers seeking help to quit were randomised (1 : 1) to receive a NRT of their choice (a single
NRT product or product combinations) plus usual care (weekly behavioural support provided by the SSS)
or e-cigarettes plus usual care. Participants attended weekly sessions at their SSS, as per standard practice,
and were followed up by telephone at 6 and 12 months. Participants reporting abstinence or at least a
50% reduction in smoking at 12 months were invited to attend for carbon monoxide (CO) validation.
Changes to the trial design
There was a change of chief investigator from Professor McRobbie to Professor Hajek (who was a
co-investigator) because Professor McRobbie moved to New Zealand. A new advertising strategy (i.e. leaflets
distributed to local households) was added. These and other minor changes are shown in Table 32 in
Appendix 1.
Participants
Inclusion/exclusion criteria
Participants were included if they were aged ≥ 18 years, were current smokers who wanted to quit
smoking and were able to read/write/understand English. Participants were excluded if they were pregnant
or breastfeeding, had a strong preference for or against using NRT or e-cigarettes in their quit attempt,
were currently enrolled in other interventional research or were currently using NRT or e-cigarettes.
Recruitment
Between May 2015 and January 2017, 886 participants were recruited. SSSs included information about
the study in their advertising (typically posters, leaflets, digital media, local papers, through general practices,
mail-outs to previous attenders and in local radio/newspaper interviews). Leaflets advertising the trial were
also delivered to local households. An example of the advertisements can be seen in the study documentation
at www.journalslibrary.nihr.ac.uk/programmes/hta/12167135/#/ (accessed 18 February 2019).
Advertisements directed participants to contact the local trial team, which provided further information
about the trial, assessed eligibility and invited potential participants to a screening session at their local SSS.
Setting
Recruitment and delivery of the interventions took place at the Health and Lifestyle Research Unit at Queen
Mary University of London (QMUL), which is commissioned to deliver the SSS for the local boroughs of
Tower Hamlets and the City of London, and the Leicester and East Sussex SSSs. Follow-up calls were carried
out by researchers at the Health and Lifestyle Research Unit.
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Trial procedures
Informed consent procedures
Following initial confirmation of eligibility by telephone/e-mail, participants were invited to attend a
screening (baseline) session at their local SSS. Potential participants were provided with written information,
along with the standard SSS client registration form, prior to their screening session. Participants were given
sufficient time to read the written information and to consider whether or not they wanted to participate.
At the screening (baseline) session, trial details were discussed and eligibility was reconfirmed. Those who
were interested and eligible gave informed consent obtained by members of staff trained in good clinical
practice.
Interventions
Identical multisession behavioural support was provided to both trial arms. The exact procedures differed
slightly between trial sites, but they followed the same treatment approach (withdrawal-oriented therapy14)
that involves face-to-face support sessions with CO monitoring, which usually begins 1 or 2 weeks prior to
the target quit date (TQD). Clients attended sessions weekly, typically for 4 weeks post TQD. Trial data
were collected face to face at the baseline session, at TQD and for the first 4 weeks post TQD.
All participants were telephoned at 26 and 52 weeks post TQD to obtain smoking status and assess
e-cigarettes/NRT/other product use and adverse reactions (ARs); at 52 weeks, those reporting abstinence
or smoking reduction of 50% or more were invited back to the service that they had attended to give
a CO reading.
Participants received £20 compensation for their time and travel at the 52-week visit. No other
compensation was provided at any time during the trial.
As per usual-care protocol, participants who missed appointments or who were not contactable at
follow-up were contacted by other means to check on their progress (i.e. text, telephone, e-mail, letter).
When there was no response, up to six attempts at contact were made at 4 weeks, up to five attempts at
6 months and up to eight attempts at 1 year.
Nicotine replacement therapy arm
Participants were advised about the NRT products available at the baseline session. They chose their
preferred NRT, as per usual practice, and were also provided with an option to use NRT combinations
(normally the patch and one of the oral products) as per usual practice. The supply of NRT differed
slightly between the different trial sites. A letter of recommendation (LOR) to supply NRT was issued on
a fortnightly basis for up to 12 weeks at the London SSS, which service users exchange at a pharmacy in
return for the NRT. The £8.60 prescription charge is paid by service users unless they are exempt (around
50% of SSS users are). East Sussex and Leicester service users receive direct supply of NRT free of charge,
for up to 12 weeks.
To avoid a possible bias that could be generated because NRT participants had to visit their local pharmacy
and potentially pay a prescription fee whereas participants randomised to e-cigarette did not, the
procedure below was followed.
At sites that used LORs, all participants were given a LOR at their baseline session (as per standard
practice). They were instructed to collect the NRT and bring it to their TQD session. At the TQD, those
METHODS
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randomised to NRT kept their NRT and initiated use at the session. Participants randomised to the
e-cigarette condition, swapped their NRT for an e-cigarette starter pack (see E-cigarette arm).
For sites that provided NRT directly, participants were provided with their NRT or e-cigarette during the
TQD session following randomisation.
For all sites, instructions on NRT use were provided as per routine clinic support.
At the completion of the trial treatment period, participants could request further supplies of NRT in line
with the SSS standard practice.
Participants in the NRT arm were free to switch to other forms of NRT; this was recorded at every contact point.
E-cigarette arm
As noted in the previous section, participants in the e-cigarette group who attended a site using LORs
were given a NRT LOR at their baseline session and were asked to collect the NRT and bring it to their TQD
session. Participants who were then randomised to e-cigarettes at the TQD swapped their NRT for the
e-cigarette starter kit. Participants randomised to the e-cigarette arm who attended a site that did not use
LORs were provided with their e-cigarette starter kit at the TQD session.
A starter pack was given to initiate e-cigarette use and demonstrate refillable e-cigarette products.
Participants were expected to source their own e-liquid and were also encouraged to purchase a different
device if the provided one did not suit their needs. To start the participants on using the e-cigarette, we
provided a Conformité Européenne (CE)-marked refillable e-cigarette with 2 or 3 weeks’ supply (1 × 30-ml
bottle) of e-liquid. The e-liquid was labelled as 18 mg/ml of nicotine, the most commonly used nicotine content
at the time.15 The e-cigarette used was ‘One Kit’, an Aspire® (Shenzhen Eigate Technology Co. Ltd, Shenzhen,
China) device with a 2.1-Ω resistance atomiser coil and a 650-mAh battery, branded by the UK Ecig Store
(London, UK). During the trial, the company discontinued the original One Kit, so the new ‘One Kit 2016’
device was used for 42 participants. One Kit 2016 is an Innokin® device (Innokin Technology, Shenzhen, China)
with a 1.5-Ω resistance atomiser coil and a 1000-mAh battery, branded by the UK Ecig Store.
The original One Kit was purchased for the wholesale price of £5.99 with the following accessories: an
atomiser five pack (£3.49), a UK adapter (£2.99) and a spare battery (£3.89). The total cost was £19.35,
including the e-liquid. The One Kit 2016 was purchased for £13 with the following accessories: an
atomiser five pack (£3.75), a UK adapter (£2.99) and a spare battery (£7.50). The total cost was £30.23,
including the e-liquid. The e-liquid used was 30 ml of Tobacco Royale flavour, purchased from the
UK Ecig Store for £2.99.
Verbal and written guidance was given about how to use the e-cigarette. Participants initiated use during
the session.
Participants were instructed to obtain further supplies of e-liquid themselves and advised on how to do
this via the internet or local vape shops. They were encouraged to try different strengths and flavours
of e-liquids if they did not like the supplied one. Participants who did not manage to source their own
supplies of e-liquid were provided with one additional supply on request (1 × 10-ml bottle), but this was
not proactively offered.
The e-cigarette arm participants had to pay for e-liquid supplies once they had used their trial-allocated
e-liquid or if they wanted to try other flavours, but these costs are modest and roughly balanced by the
fact that some of the NRT arm participants had to pay prescription charges.
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Both trial arms
To help minimise contamination, at the TQD all participants in both trial arms were asked to sign a
commitment form stating that they were committed to not using the non-allocated treatment for at least
4 weeks post TQD.
Measurements
Measurements were collected as follows:
l participant demographics, smoking history and previous/current medical conditions
l Fagerström Test for Cigarette Dependence (FTCD) score16
l score on the Mood and Physical Symptoms Scale, which measures severity of urges to smoke and other
tobacco withdrawal symptoms17
l self-reported smoking status
l end-expired CO reading, collected using a CO monitor [a reading of < 8 parts per million (p.p.m.) was
used as a cut-off point for validating self-reported abstinence]
l an ARs checklist (see Adverse reactions)
l e-cigarette/NRT use and ratings of helpfulness in refraining from smoking cigarettes (from 1 = not at
all helpful to 5 = extremely helpful) and satisfaction and how good it tasted in comparison with usual
cigarettes (much less than normal cigarettes = 1, a little less = 2, the same = 3, a little more = 4, much
more than normal cigarettes = 5)
l in the case of participants who stopped using e-cigarettes/NRT or who switched to a different type of
e-cigarette/NRT, reasons for doing so
l additional economic evaluation measures: EuroQoL-5 Dimensions, five-level version (EQ-5D-5L), score at
baseline and at 6 and 12 months;18 smoking cessation service and health service use at baseline and
during the preceding period at 6 and 12 months.
Adverse reactions
With the agreement of the trial sponsor and Research Ethics Committee (REC), data on adverse events
(AEs) were not collected, as the safety profiles of NRT are well established and a number of studies4,19
have now identified the likely ARs to e-cigarettes. Instead, an ARs checklist was used (Table 1 shows the
schedule of collection of measurements), which asked whether or not any ARs had been experienced since
the last contact. Those reporting ARs were asked whether the AR had stopped them from doing things
they would usually do, as an indication of severity. The following were evaluated at each session: nausea,
throat/mouth irritation, sleep disturbances, dizziness, headache and four indicators of respiratory health:
shortness of breath, cough, wheezing and phlegm.
Serious adverse events (SAEs), including death, overnight hospitalisation and permanent disability, were
also recorded.
Data management
Data collection and entry
A web-based application, using an Oracle 11g database, was used to collect data. This was set up and hosted
by the Barts Clinical Trials Unit (CTU). The electronic data capture forms were web based and built using Java
(Oracle Corporation, Redwood Shores, CA, USA) with data validation in JavaScript (Java framework Struts 2)
(Netscape Communications Corporation, Dulles, VA, USA; Mozilla Foundation, Mountain View, CA, USA;
Ecma International, Geneva, Switzerland). When the web-based application was unavailable, data were
METHODS
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collected on paper case report forms (CRFs) and questionnaires and then entered into the database at the
earliest opportunity. All data were kept in accordance with good clinical practice and data protection
requirements.
Data quality
The co-ordinating site checked electronic CRFs on a weekly basis for anomalies and raised and resolved
queries with the researcher/advisor concerned. Once recruitment and follow-up were complete, the trial
team cleaned the data.
A sample of paper CRFs/questionnaires were also checked. Ten per cent were randomly selected for
comparison between written and database entries. The predetermined quality target of ≤ 2%
discrepancies was met.
TABLE 1 Schedule of assessments
Measures/procedures
Trial session
Baseline TQD
TQD+
1 week
TQD+
2 weeks
TQD+
3 weeks
TQD+
4 weeks
TQD+
26 weeks
TQD+
52 weeks
Informed consent ✓
Baseline questionnaire ✓
Current illness ✓ ✓ ✓ ✓ ✓ ✓ ✓
Current medication ✓ ✓ ✓ ✓ ✓ ✓ ✓
Randomisation ✓
Commitment form ✓
CO reading ✓ ✓ ✓ ✓ ✓ ✓ ✓ (if abstinent
or there was a
50% reduction)
MPSS ✓ ✓ ✓ ✓
Smoking status/CPD ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
ARs ✓ ✓ ✓ ✓ ✓ ✓
E-cigarette/NRT ratings ✓ ✓
E-cigarette/NRT use and
helpfulness
✓ ✓ ✓ ✓ ✓ ✓ ✓
E-cigarette dispensed,
demonstration on first use
✓ ✓
NRTa dispensed,
demonstration on first use
✓ ✓ ✓
EQ-5D-5L questionnaire ✓ ✓ ✓
Smoking cessation service
and health service use
✓ ✓ ✓
CPD, cigarettes per day; MPSS, Mood and Physical Symptoms Scale.
a Dispensing sessions differed slightly between sites depending on local SSS practices.
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Sample size
At the time the trial protocol [available at www.journalslibrary.nihr.ac.uk/programmes/hta/12167135/#/
(accessed 23 April 2019)] was drawn up, the 12-month validated abstinence rate (i.e. the primary outcome)
associated with usual care in our setting was 14%.20 The projection of a feasible rate with the e-cigarettes
was based on the research team’s work and two published studies. The research team’s work suggested that
e-cigarettes deliver nicotine quickly, with time to the maximum concentration occurring within 5 minutes.21
This is similar to nicotine nasal spray. In a comparative study of nicotine nasal spray plus patch versus patch
alone, 1-year abstinence rates were 27% versus 11%, respectively [risk ratio (RR) 2.45].22 In a 2014 cohort
study23 in Italy, a second-generation e-cigarette achieved 36% CO-validated abstinence at 6 months.
Assuming 25% relapse between 6 and 12 months,24 this would translate to a 1-year abstinence rate of 27%.
Relative to the assumed usual care rate, this would give a RR of 1.9. However, quit rates in countries with little
tradition of stop smoking treatments tend to be much higher than in the UK. The research team wanted to
detect a RR of 1.7 (e-cigarette rate = 24%) with 0.95 power, but also have reasonable power (e.g. 0.75) if the
RR should be as low as 1.5 (e-cigarette rate = 21%). This figure still represents a clinically significant difference.
To achieve these levels of power (two-sided alpha = 0.05, continuity correction), a total of 886 participants
(443 in each group) was required.
It is noted in the statistical analysis plan that, since the trial protocol was written, a new evaluation of the UK
SSSs has been published.25 The validated 1-year quit rate has declined to 8%. This figure is derived from quit
rates in general practice and pharmacy services of 5% and in specialist support services of 10% for individual
and 12% for group support. The decline is probably a result of a ‘hardening’ of treatment population, namely
the services see an increasing number of reattenders, people with serious health issues, etc. Using a quit
rate of 10% in the usual-care arm, which provides multicontact support, and 17% in the e-cigarette arm
(RR 1.70), the trial sample size still provides at least 85% power to detect such a difference with a two-tail
test of proportions.
Assuming that the true percentage in both arms is 10%, the 95% confidence interval (CI) for the
difference in proportions will have a width of ± 4% around the observed difference.
Randomisation
Randomisation (1 : 1 in permuted blocks of 20) was undertaken using a web-based application, set up by
the Barts CTU, and was stratified by trial site. Participants who were eligible and consented to take part
were randomly allocated to the NRT arm or the e-cigarette arm on the TQD session by researchers/stop
smoking advisors. The TQD was used as the point of randomisation to minimise any differential drop-out.
The staff randomising the participant accessed the web-based application when the participant was with
them, entering their participant identification number, date of birth and initials into the program. There
were no stratification factors. The allocation was immediately provided by the program. In the event of the
site having no web access, staff were able to fax/e-mail the relevant CRFs to the CTU for a telephone
randomisation to take place during standard working hours.
Treatment blinding
Participants could not be blinded to the intervention they were receiving, and trial staff could not be
blinded when providing the interventions and collecting data.
Unblinded data were seen and analysed by the trial statistician for the purposes of the Data Monitoring
and Ethics Committee (DMEC) meetings. All other trial staff who had access to outcome data remained
blinded until prespecified data analyses were complete. Prespecified data analyses were conducted blind to
treatment allocation.
METHODS
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Statistical methods
Changes from planned analysis
There were no changes from the planned analysis, from either the trial protocol or the statistical analysis
plan. See the project web page for the statistical analysis plan [www.journalslibrary.nihr.ac.uk/programmes/
hta/12167135/#/ (accessed 18 February 2019)].
General analysis principles
The main analysis for each outcome used intention-to-treat principles, meaning that all participants with a
recorded outcome were included in the analysis and were analysed according to the treatment group to
which they were randomised. More information on which participants were included in each analysis is
available in Withdrawn participants.
In all analyses for all outcomes, the following are presented:
l the number of participants included in the analysis, by treatment group (for the primary outcome data,
this will be all randomised participants; see the next section)
l a summary measure of the outcome by treatment group, for example mean [standard deviation (SD)]
for continuous outcomes and number (%) for binary outcomes
l treatment effect (risk ratio of abstinence for e-cigarettes relative to NRT), with 95% CI
l two-sided p-values (the significance level was set at 5%).
Missing data
To deal with incomplete data (i.e. when patients had missing data at one of the follow-up time points),
the research team:
l attempted to follow up all randomised patients, even if they had discontinued participation
l included participants lost to follow-up (i.e. missing cases) or not providing biochemical validation as
non-abstainers
l carried out sensitivity analyses using multiple imputations via chained equation and excluding cases with
missing outcomes.
Withdrawn participants
Participants requesting no further follow-up were included in the analysis, as per intention to treat (such
participants were counted as smokers for the time points after withdrawal, as per the Russell Standard26).
Participants who died were excluded from the sample, as per the Russell Standard.
Participants who moved to an untraceable address and whose telephone number(s) and e-mail address
were no longer in use were excluded from the sample from the point that notification was received that
they were no longer living at the address and their telephone number(s)/e-mail address were no longer in
use, as per the Russell Standard. They were included in the sample analysis up until this point and coded
as relapsed after that point.
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Chapter 3 Outcomes
Some parts of this chapter are from The New England Journal of Medicine, Hajek P, et al.
13 A randomized
trial of e-cigarettes versus nicotine-replacement therapy, Vol. 380, pp. 629–37. Copyright © 2019
Massachusetts Medical Society. Reprinted with permission.
Primary outcome
Sustained abstinence at 52 weeks was calculated as per the Russell Standard26 (i.e. a self-report of smoking
no more than five cigarettes since 2 weeks post TQD), validated by a CO reading of < 8 p.p.m. at the 52-week
follow-up. (CO in expired breath is a commonly used biochemical validation tool that is particularly useful
when people continue to use nicotine because methods based on the detection of nicotine metabolites
are not appropriate in such cases. The CO assay detects only smoking over the previous ≈24 hours, but trial
participants do not usually know of the assay’s half-life, and dependent smokers typically smoke daily.)
If outcome data at previous follow-up points were missing but no data were available to contradict claims
of sustained abstinence, the participants who reported smoking no more than five cigarettes in total since
2 weeks post TQD at the 52-week follow-up and whose self-report was validated by a CO reading of
< 8 p.p.m. were classed as meeting the primary outcome definition.
In the primary analysis, all participants were included in the arm to which they were randomised, but
sensitivity analyses were conducted that took into account use of non-allocated products.
Sensitivity analyses for primary outcome
The following sensitivity analyses of the primary outcome were conducted:
l including only participants who attended at least one treatment session, namely only those who
engaged in treatment
l excluding participants who used the unassigned trial product for 5 consecutive days or more
l using multiple imputation of smoking status in participants with missing follow-up data by
chained equations.
At the request of the chairperson of the Trial Steering Committee (TSC), an analysis limited to participants
who completed the 12-month follow-up is also included. (This is normally not done in this field, as it
increases quit rates and can obscure treatment effects; treatment failures are more likely to drop out, and
so missingness is not random.)
Secondary outcomes
We examined the differences between study arms in the proportions of participants with 6- to 12-month
sustained abstinence, abstinence at 4 and 26 weeks, and sustained reduction of 50% or greater in baseline
cigarette consumption and CO levels at 52 weeks, using binomial regression.
At each time point, seven-day abstinence rates were also calculated. This measure is less informative
because 7 days of not smoking does not convey much health benefit and, compared with sustained
abstinence, is a weak predictor of smoking status in future. Seven-day abstinence is also influenced by
other, more recently occurring factors, so is likely to diminish the effects of a treatment delivered 1 year ago.
However, it is still used in less rigorous studies and so it was included to allow across-trial comparisons.
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The time to relapse was examined using a Cox analysis.
Table 2 shows the definitions used for secondary outcomes.
Each outcome was adjusted for baseline covariates selected using a stepwise regression approach so that
only significant covariates (p = 0.1) were included in the final model.
Tobacco withdrawal symptoms at 1 and 4 weeks
Between-group differences in urges to smoke and changes (from baseline) in tobacco withdrawal
symptoms were examined using t-tests in both the whole sample and the abstainers-only sample.
Treatment ratings (satisfaction, taste, helpfulness, reasons for stopping
product use)
Differences in mean ratings of satisfaction, taste of the product, product helpfulness and reasons for stopping
product use were examined between groups using t-tests at 1 and 4 weeks post TQD. Adjustments for
normal distribution were applied when needed and non-parametric tests were used where necessary. When
two NRT products were used and rated, the average rating of the two was taken.
Adverse reactions
The chi-squared test was used to compare, between arms, the frequency of participants who reported
each AR (sleep disturbance, nausea or throat/mouth irritation) on at least one occasion. The Medical
Dictionary for Regulatory Activities (MedDRA) coding system was used.
TABLE 2 Secondary outcome definitions
Outcome Definition
CO-validated sustained abstinence between
26 and 52 weeks post TQD
Reporting no more than five cigarettes smoked between weeks 26 and
52, accompanied by a CO reading of < 8 p.p.m. at week 52
For all outcomes, if data from previous follow-ups were missing but no
data contradicted the outcome as measured at the given point, this was
accepted
CO-validated sustained abstinence at 4 weeks
post TQD
Reporting not a single puff in the previous 2 weeks at Q + 4 follow-up,
accompanied by a CO reading of < 8 p.p.m. at Q + 4
Sustained abstinence at 26 weeks post TQD Reporting no more than five cigarettes smoked since 2 weeks post
TQD at Q + 24
7-day point prevalence at 4 weeks post TQD Reporting not a single puff in the previous 7 days
7-day point prevalence at 26 weeks post TQD Reporting not a single puff in the previous 7 days
7-day point prevalence at 52 weeks post TQD Reporting not a single puff in the previous 7 days
Smoking reduction in participants who did not
achieve abstinence at 52 weeks
Self-reported daily cigarette consumption at Q+ 52 reduced by at least
50% from baseline consumption, accompanied by a CO reading at
Q + 52 reduced by at least 50% from that at baseline. Participants with
missing data were classified as non-reducers
Q+ 4, contact at 4 weeks post TQD; Q + 24, contact at 24 weeks post TQD; Q + 52, contact at 52 weeks post TQD.
OUTCOMES
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Changes in respiratory symptoms
Using logistic regression, we compared changes in cough, wheezing, phlegm production and shortness of
breath from baseline to 52 weeks in the two arms. Symptoms at 52 weeks were regressed onto trial arm
with adjustment for baseline score and study site.
The details of the cost-effectiveness analysis methods are included in the cost-effectiveness section.
Statistical software
All analyses were carried out using Stata® software, version 15 (StataCorp LP, College Station, TX, USA).
Patient and public involvement
Two members of the public served on the TSC. Along with two others, they also contributed to a patient
and public involvement (PPI) panel, which convened throughout the trial. Three members of the panel
were current e-cigarette users. When PPI members were not available for the meetings/teleconferences,
they were contacted by e-mail for their feedback.
Trial committees
The DMEC and the TSC convened every 6–12 months. The Trial Management Group also met regularly
throughout the study. Appendix 1, Table 33, shows the members of the trial committees.
The chief investigator, study manager and a minute-taker (who was a member of the trial team) also
attended the TSC and DMEC meetings. The trial statistician (originally Mr John Stapleton, followed by
Dr Irene Kaimi) also attended the DMEC meetings.
Quality control and quality assurance
A risk assessment was carried out in conjunction with the trial sponsor and Barts CTU, which was used as
a basis for the trial monitoring plan. During the recruitment phase, a monitor from the co-ordinating site
carried out 6-monthly monitoring visits at each of the sites. The Barts CTU was responsible for oversight of
the monitoring process and overall audit of the trial.
Approvals
The trial was sponsored by the QMUL Joint Management Research Office. Ethics approval was obtained
from the National Research Ethics Service Committee London – Camden and Islington REC on
19 December 2014 (reference number14/LO/2235).
The results and the discussion of the Trial of E-Cigarettes (TEC) are presented in Chapter 4. The methods
and results of the economical evaluation are presented in Chapter 5.
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Chapter 4 The TEC trial
Some parts of this chapter are from The New England Journal of Medicine, Hajek P, et al.
13 A randomized
trial of e-cigarettes versus nicotine-replacement therapy, Vol. 380, pp. 629–37. Copyright © 2019
Massachusetts Medical Society. Reprinted with permission.
Results
The methods and results of the economical evaluation are presented after the main trial section.
Participant flow
Figure 1 shows the Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
The follow-up rates at 12 months were 81% in the e-cigarette arm and 77% in the NRT arm [χ2(1) = 2.1;
p = 0.09].
Sample characteristics
Participant characteristics are shown in Table 3.
The sample comprised mostly middle-aged smokers who started to smoke at a median age of 16 years
and tried various smoking cessation aids before joining the trial.
Abstinence rates
Table 4 shows abstinence rates in the two trial arms at different time points. Abstinence rates were
consistently higher with e-cigarettes than with NRT for both primary and secondary outcomes. There were
no significant differences between quit rates across the trial sites [e.g. χ2(2) = 4.2; p = 0.12 for the primary
outcome].
Sensitivity analyses for the primary outcome
Regarding the primary outcome, sustained 1-year abstinence rates were 18.0% and 9.9% in the
e-cigarette and NRT arms, respectively (RR 1.83, 95% CI 1.30 to 2.58; p = 0.001) (see Table 4). The results
of the four sensitivity analyses of the primary outcome tallied with the main analysis, indicating greater
abstinence in the e-cigarette arm than in the NRT arm (RR 1.75 to RR = 1.85; p < 0.001) (Table 5). The
absolute risk difference for the primary outcome was 8.1% (95% CI 3.6% to 12.7%), with a number
needed to treat of 12.
Among the e-cigarette arm abstainers, two (3%) were using non-allocated NRT at 12 months, whereas,
in the NRT arm, nine (20%) were using non-allocated e-cigarettes. An additional sensitivity analysis that
was not prespecified, in which the abstainers using non-allocated products were removed from the
sample, was carried out. This per-protocol analysis resulted in a 52-week abstinence rate in the e-cigarette
and NRT arms of 17.7% and 8.0%, respectively (RR 2.21, 95% CI 1.52 to 3.22; p < .001).
Table 4 also shows the secondary abstinence outcomes. Abstinence rates were consistently higher in the
e-cigarette arm, including 7-day point prevalence abstinence rates (Table 6).
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Referred as eligible and re-screened
(n = 1047)
Not eligible
(n = 14)
Randomised
(n = 886)
Allocated to e-cigarettes
(n = 439)
Completed 4-week follow-up
(n = 376)
Completed 6-month follow-up
(n = 352)
Completed 12-month follow-up
(n = 356)
Included in primary outcome, n = 438
• Died during the study, n = 1 (excluded)
• Stopped treatment and refused
   follow-up, n = 3
• Stopped treatment and permitted
   follow-up, n = 13 (all included)
Allocated to NRT
(n = 447)
Completed 4-week follow-up
(n = 356)
Completed 6-month follow-up
(n = 337)
Completed 12-month follow-up
(n = 342)
Included in primary outcome, n = 446
• Died during the study, n = 1 (excluded)
• Stopped treatment and refused
   follow-up, n = 5
• Stopped treatment and permitted
   follow-up, n = 36 (all included)
Not eligible
(n = 463)
Screened for eligibility by
phone/e-mail
(n = 2045)
Attended ≥ 1 session post TQD
(n = 432)
Attended ≥ 1 session post TQD
(n = 438)
Eligible but did not attend 
baseline session
(n = 535)
Did not attend for randomisation
(n = 147)
FIGURE 1 The CONSORT flow diagram. From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-
replacement therapy. The New England Journal of Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts
Medical Society. Reprinted with permission.
THE TEC TRIAL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
TABLE 3 Sample characteristics
Characteristic
Trial arm
Total
(N= 884)
E-cigarette
(N= 438)
NRT
(N= 446)
Age (years), median (IQR) 41 (33–53) 41 (33–51) 41 (33–52)
Female, n (%) 211 (48.2) 213 (47.8) 424 (48.0)
Marital status, n (%)
Single 224 (51.1) 249 (55.8) 473 (53.5)
Separated or divorced 89 (20.1) 86 (19.3) 174 (19.6)
Married 116 (26.5) 105 (23.5) 221 (24.9)
Widowed 10 (2.3) 6 (1.4) 16 (1.8)
Ethnicity, n (%)
White British 322 (73.5) 311 (69.7) 633 (71.6)
White other 35 (8.0) 41 (9.2) 76 (8.6)
Black 15 (3.4) 15 (3.4) 30 (3.4)
Asian 29 (6.6) 37 (8.3) 66 (7.5)
Mixed 22 (5.0) 28 (6.3) 50 (5.7)
Other 9 (2.1) 9 (2.0) 18 (2.0)
Missing 6 (1.4) 5 (1.1) 11 (1.2)
Educational qualification, n (%)
Primary school 19 (4.3) 22 (4.9) 41 (4.6)
Secondary school 141 (32.2) 130 (29.2) 271 (30.7)
Further education/diploma 117 (26.7) 127 (28.5) 244 (27.6)
Higher education 161 (36.7) 167 (37.5) 328 (37.1)
Employment status, n (%)
In paid employment 299 (68.3) 316 (70.9) 615 (69.6)
Receives free prescriptions, n (%) 181 (41.3) 179 (40.1) 360 (40.7)
Smoking and quitting history
Cigarettes smoked per day, median (IQR) 15 (10–20) 15 (10–20) 15 (10–20)
Baseline CO, median (IQR) 20 (13–27) 21 (13–28) 20 (13–28)
FTCD, mean (SD) 4.5 (2.5) 4.6 (2.4) 4.6 (2.4)
Previous use of stop smoking products, n (%)
NRT 328 (74.9) 334 (74.9) 662 (74.9)
Varenicline (Champix®; Pfizer Inc., New York City, NY, USA) 149 (34.1) 151 (33.8) 300 (33.9)
Bupropion (Zyban®; GlaxoSmithKline plc, Brentford, UK) 34 (7.8) 35 (7.9) 69 (7.8)
E-cigarettes 186 (42.5) 181 (40.6) 367 (41.5)
Never tried NRT, varenicline or bupropion 84 (19.2) 92 (20.6) 176 (19.9)
Age (years) initiated smoking, median (IQR) 16 (14–18) 16 (14–18) 16 (14–18)
Spouse/partner smokes, n (%) 167 (38.1) 178 (39.1) 345 (39.1)
Study site, n (%)
London 289 (66.0) 295 (66.2) 584 (66.1)
Leicester 92 (21.0) 96 (21.5) 188 (21.3)
East Sussex 57 (13.0) 55 (12.3) 112 (12.7)
IQR, interquartile range.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
DOI: 10.3310/hta23430 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 43
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hajek et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Among participants who did not achieve full abstinence, more participants in the e-cigarette arm than in
the NRT arm achieved a validated reduction of smoking of ≥ 50% (see Table 6).
Time to relapse was not significantly different in the two trial arms (HR 1.14, 95% CI 0.96 to 1.34;
p = 0.12). The relapse rates at 1 year among 4-week abstainers did not differ between the two trial arms
(RR 1.27, 95% CI 0.93 to 1.73; p = 0.14).
Figure 2 shows the time to relapse in the two conditions.
TABLE 4 Sustained CO-validated abstinence rates at each time point and 52-week CO-validated smoking reduction
Outcome
Trial arm, n (%) Unadjusted Adjusted
E-cigarette
(N= 438)
NRT
(N= 446)
Relative risk
(95% CI)a p-value
Relative risk
(95% CI) p-value
Primary outcome
52-week abstinence 79 (18.0) 44 (9.9) 1.83 (1.30 to 2.58) 0.001 1.75 (1.24 to 2.46)b 0.001
Secondary outcomes
Abstinence between 26
and 52 weeks
93 (21.2) 53 (11.9) 1.79 (1.32 to 2.44) < 0.001 1.82 (1.34 to 2.47)c < 0.001
4 weeks post TQD 192 (43.8) 134 (30.0) 1.45 (1.22 to 1.74) < 0.001 1.43 (1.20 to 1.71)d < 0.001
26 weeks post TQD 155 (35.4) 112 (25.1) 1.40 (1.14 to 1.72) 0.001 1.36 (1.15 to 1.67)b 0.003
CO-validatede reduction
≥ 50% in non-abstainers
at 24–52 weeks; n/N (%)
44/345 (12.8) 29/393 (7.4) 1.75 (1.12 to 2.72) 0.01 1.73 (1.11 to 2.69) 0.02
a Adjusted for study site only.
b Adjusted for study site, age started smoking, marital status, FTCD.
c Adjusted for study site, age, FTCD, age started smoking.
d Adjusted for study site, education, partner smoking, FTCD.
e Adjusted for study site, sex, age, partner smoking.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
TABLE 5 Sensitivity analyses for the primary outcome
Sensitivity analysesa RR p-value 95% CI
Participants who attended ≥ 1 treatment session
(e-cigarette arm, n = 411; NRT arm, n = 418)
1.79 0.001 1.27 to 2.52
Participants using non-allocated product for ≥ 5 days excluded
(e-cigarette arm, n = 411; NRT arm, n = 345)
1.84 0.001 1.27 to 2.66
Participants with missing outcome at 52 weeks excluded (e-cigarette arm, n = 356;
NRT arm, n = 342)
1.75 0.001 1.25 to 1.45
Multiple imputation of missing information by chained equations (e-cigarette arm,
n = 438; NRT arm, n = 446)
1.85 < 0.001 1.32 to 2.60
a Adjusted for trial site.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
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Attendance and adherence
Table 7 shows session attendance and adherence to each treatment and length of NRT/e-cigarette use.
Adherence to e-cigarettes was greater from early on, with many more participants still using e-cigarettes at
6 and 12 months, while only a few still used NRT.
Of the 19 participants in the NRT arm using NRT at 12 months, four were using NRT combinations.
Products used were patches (n = 7), chewing gum (n = 6), mouth spray (n = 5), inhalator (n = 2), mouth
strips, microtabs and lozenge (n = 1 each). Of the 173 participants in the e-cigarette arm using e-cigarettes
at 12 months, 168 (97%) used refillable products.
Table 8 shows reasons for discontinuing product use. Participants in the NRT arm were more likely to
dislike the taste, have ARs and find the product not satisfying.
Overall, there were more participants assigned to NRT who used e-cigarettes than participants assigned
to e-cigarettes who used NRT. The initial cross-contamination levels were low. A 15% level of cross-
contamination in the first 4 weeks post TQD was predefined as being acceptable; the reported level was
< 3%. Cross-contamination was defined as non-allocated product use on at least 5 consecutive days.
TABLE 6 Seven-day smoking abstinence at each follow-up
7-day smoking
abstinence at each
follow-up
Trial arm, n (%) Unadjusted Adjusted
E-cigarette
(N= 446)
NRT
(N= 438)
Relative risk
(95% CI) p-value
Relative risk
(95% CI) p-value
4 weeks post TQD 195 (44.4) 136 (30.4) 1.46 (1.23 to 1.74) < 0.001 1.43 (1.20 to 1.70)a < 0.001
26 weeks post TQD 158 (36.0) 115 (25.7) 1.39 (1.14 to 1.70) 0.001 1.36 (1.12 to 1.66)b 0.002
1 year post TQD 146 (33.3) 98 (21.9) 1.52 (1.23 to 1.90) < 0.001 1.52 (1.22 to 1.89)c < 0.001
a Adjusted for trial site, age, FTCD, ethnicity, age started smoking.
b Adjusted for trial site, age, FTCD, ethnicity, marital status, age started smoking.
c Adjusted for trial site, partner smokes.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
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FIGURE 2 Time to relapse.
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TABLE 7 Adherence to treatment
Measure of adherence
Trial arm
p-value χ2, ZE-cigarette (N= 438) NRT (N= 446)
Number of contacts completed,a median (IQR) 5 (4–5) 5 (4–5)
Maximum sessions completed, n (%)
1 8 (1.8) 10 (2.2) χ2(4) = 8.8;
p = 0.07
2 25 (5.7) 40 (9.0)
3 38 (8.7) 45 (10.1)
4 86 (19.6) 106 (23.8)
5 281 (64.2) 245 (54.9)
Use of allocated products over the initial 4 weeksb
On how many days used (0–28), median (IQR) 28 (25–28) 24 (19–27) < 0.001 Z = 11.6
n (%) using daily over the full 4 weeks 232 (53.0) 46 (10.3) < 0.001 χ2(1) = 186.5
Days used in past week, median (IQR)
(the results were similar for weeks 1–4)
7 (7–7) 6.5 (3.5–7) < 0.001 Z = 8.1–9.1
Use of allocated products at 26 weeks
n (%) using at 26 weeks 180 (41.1) 33 (7.4) < 0.001 χ2(1) = 137.2
Use of allocated products at 52 weeks
n (%) using at 52 weeks 173 (39.5) 19 (4.3) < 0.001 χ2(1) = 161.4
a Maximum of five contacts: preparation, 1 week, 4 weeks, 6 months and 12 months.
b Throughout the table, apart from ‘sessions completed’, missing data were imputed from the data from the following
sessions where available (e.g. for missing data at event 3, data were taken from event 4).
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
TABLE 8 Reasons for stopping allocated product use in those discontinuing use during the initial 4 weeks
Reason
Trial arm, n (%)
E-cigarette (N= 88) NRT (N= 166)
Cost 0 (0) 0 (0)
Did not like the taste 4 (4.6) 19 (11.5)
AR 7 (8.0) 25 (15.1)
Not satisfying 4 (4.6) 16 (10.0)
Difficult to use 2 (2.3) 1 (0.6)
Embarrassing to use 0 (0) 1 (0.6)
Difficult to obtain them 0 (0) 1 (0.6)
Smoking normal cigarettes now 8 (9.1) 17 (10.2)
To quit nicotine 0 (0) 6 (3.6)
Other 63 (71.6) 80 (48.2)
THE TEC TRIAL
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However, later in the trial, more people from the NRT arm were using e-cigarettes than the other way
round. Participants who switched from NRT to e-cigarettes also used the non-allocated product for longer
than those who switched from e-cigarettes to NRT. Similar very low proportions of participants in both trial
arms used other stop smoking medications during the first 4 weeks (Table 9).
Table 10 shows the NRT products selected initially by the participants in the NRT arm.
The majority of participants (88.1%) received two NRT products. The nicotine patch was by far the most
popular, followed by the nicotine inhalator and nicotine mouth spray. Switching to different NRT products
during the first 4 weeks of treatment was fairly common (see Table 10).
Table 11 shows the e-cigarette products used by participants in the e-cigarette arm. Most of those who
used e-cigarettes began purchasing e-liquid themselves from early on; very few requested e-liquid supply
beyond the first bottle. Hardly any participants (< 1%) switched to a cartridge e-cigarette. The nicotine
strength of the e-liquid declined over time. Flavour choices varied with time; fruit and tobacco flavours
were most popular, with mint and chocolate/candy flavours following (Table 12).
Table 13 compares ratings of NRT and e-cigarettes in terms of perceived helpfulness in stopping smoking,
and in terms of taste and satisfaction compared with conventional cigarettes. Only cases with complete
data across measures are included. E-cigarettes received significantly better ratings for all three variables at
both time points. Both products were perceived as less satisfying compared with cigarettes, but e-cigarettes
provided higher satisfaction than NRT (see Table 13).
Urges to smoke
Table 14 shows urges to smoke in participants abstaining from smoking at 1 and 4 weeks post TQD in the
two trial arms. Participants in the e-cigarette arm experienced lower frequency of urges to smoke and
reduced strength of urges than participants in the NRT arm.
TABLE 9 Non-allocated product use
Non-allocated product use
Trial arm
p-value t-value/χ2
E-cigarette
(N= 438)
NRT
(N= 446)
Non-allocated product use within the first 4 weeks
Used for ≥ 5 consecutive days, n (%) 3 (0.7) 11 (2.5) 0.06 Fisher’s exact test
Non-allocated product use at 6 months (excludes first 4 weeks)
Used for ≥ 5 consecutive days since 4 weeks, n (%) 16 (3.6) 57 (12.8) < 0.001 χ2(1) = 24.3
Duration (in weeks) of non-allocated product use since
previous assessment (0–20), median (IQR)
3 (1–9) 8 (1–20) 0.2 Z = –1.2
Non-allocated product use at 12 months (excludes first 4 weeks)
Used for ≥ 5 consecutive days since 26 weeks, n (%) 14 (3.2) 77 (17.3) < 0.001 χ2(1) = 47.4
Duration (in weeks) of non-allocated product use
since previous assessment (0–24), median (IQR)
6.5 (0–12) 20 (6–24) 0.002 Z = –3.1
Other non-study stop smoking medication use (including single use)
Varenicline, n (%) 15 (3.4) 13 (2.9) 0.7
Bupropion, n (%) 0 (0) 0 (0) N/A
N/A, not available.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
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TABLE 10 The NRT products used
NRT products used n (%)
Type of NRT selected initially N = 442a,b
24-hour patch (21mg) 190 (43)
24-hour patch (14mg) 4 (1)
16-hour patch (25mg) 149 (34)
16-hour patch (15mg) 29 (7)
16-hour patch (10mg) 1 (0.2)
Microtab (2 mg) 0
Mouth strips (2.5 mg) 68 (15)
Gum (4mg) 25 (6)
Gum (2mg) 8 (2)
Lozenge (4 mg) 20 (5)
Lozenge (2 mg) 17 (4)
Nasal spray 2 (0.5)
Minis (4 mg) 33 (8)
Minis (1.5 mg) 2 (0.5)
Inhalator 163 (37)
Mouth spray 124 (28)
Selecting two NRT products 393 (88)
Switched to different NRT product in first 4 weeks 260 (59)
a Information is missing for four participants.
b Participants may report using more than one product, which is why the total does not add up to 446.
TABLE 11 The e-cigarette products used
E-cigarette products used
E-cigarette arm participants using refillable e-cigarettes, n (%)
1 week post TQD (N = 384)a 383 (99.7)
4 weeks post TQD (N = 343)a 343 (100)
26 weeks post TQD (N = 270)a 265 (98.2)
52 weeks post TQD (N = 235)a 227 (96.6)
E-liquid nicotine strength in mg/ml, median (IQR)
4 weeks post TQD (N = 340) 18 (16–18)
26 weeks post TQD (N = 267) 12 (6–18)
52 weeks post TQD (N = 232) 11 (5–18)
Requested further e-liquid supply at 2 weeks post TQD, n (% of full sample) 30 (7)
a Percentage was calculated from number providing information.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
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TABLE 12 The e-cigarette flavours used
Flavoura
Week, n (%)
1 (N= 155) 4 (N= 156) 26 (N= 516) 52 (N= 511)
Tobacco 15 (10) 44 (28) 163 (32) 127 (25)
Fruit 70 (45) 51 (33) 150 (30) 169 (33)
Menthol/mint 31 (20) 20 (13) 75 (15) 81 (16)
Tobacco menthol 5 (3.2) 7 (4.5) 13 (2.5) 12 (2.3)
Vanilla 5 (3.2) 1 (0.6) 11 (2.1) 14 (2.7)
Chocolate, dessert, candy or sweet 17 (11) 18 (12) 62 (12) 72 (14)
No flavour 0 (0) 0 (0) 0 (0) 2 (0.4)
Coffee 2 (1.3) 1 (0.6) 6 (1.2) 8 (1.6)
Alcoholic drink 2 (1.3) 2 (1.3) 7 (1.4) 3 (0.6)
Energy or soft drink 6 (3.9) 10 (6.4) 17 (3.3) 13 (2.5)
Other 2 (1.3) 2 (1.3) 12 (2.3) 10 (2.0)
a Some participants used more than one flavour; numbers and percentages are based on the total number of entries.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
TABLE 13 E-cigarette/NRT helpfulness and their taste and satisfaction compared with cigarettes
Rating
Trial arm, mean (SD)
t-value; p-value
Mean difference
(95% CI)
E-cigarette
(n= 324)a NRTb (n= 228)a
Helpfulnessc
1 week post TQD 4.3 (0.9) 3.6 (0.9) 8.4; < 0.001 0.7 (0.5 to 0.9)
4 weeks post TQD 4.3 (0.9) 3.7 (0.9) 7.0; < 0.001 0.6 (0.4 to 0.7)
Tasted
1 week post TQD 3.0 (1.4) 2.7 (1.6) 2.5; 0.015 0.3 (0.1 to.06)
4 weeks post TQD 3.5 (1.3) 3.1 (1.5) 3.3; 0.001 0.4 (0.2 to 0.6)
Satisfactiond
1 week post TQD 2.4 (1.0) 2.0 (1.2) 4.3; < 0.001 0.4 (0.2 to 0.6)
4 weeks post TQD 2.7 (1.1) 2.3 (1.2) 4.7; < 0.001 0.5 (0.3 to 0.6)
a Where two types of NRT were used, the average rating was taken.
b Cases where data is missing across measures are excluded.
c Helpfulness in keeping participant from cigarettes was rated as 1 = not at all helpful to 5 = extremely helpful.
d Satisfaction and how good the product tasted compared with cigarettes was rated as 1 =much less than normal
cigarettes, 2 = a little less than normal cigarettes, 3 = the same as normal cigarettes, 4 = a little more than normal
cigarettes, 5 = much more than normal cigarettes.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
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Among all participants, the level of urges to smoke is higher, but the difference between the two trial
arms is similar, with the e-cigarette arm reporting lower frequency of urges to smoke and reduced urge
intensity than the NRT arm (Table 15).
Withdrawal symptoms
Regarding other withdrawal symptoms, abstainers in the e-cigarette arm suffered less restlessness,
irritability and inability to concentrate during the first week of abstinence. By week 4, abstainers in both
trial arms suffered little discomfort and the differences were no longer significant (Table 16). Among all
participants, irritability, restlessness, hunger, poor concentration and the composite withdrawal score were
all less severe in the e-cigarette arm than in the NRT arm during the first week of abstinence, with only the
difference in hunger and the composite withdrawal score persisting at week 4 (Table 17).
Product safety
Safety of the trial products was evaluated in three ways: SAEs were recorded, data were collected on
elicited ARs, and changes in respiratory symptoms over the duration of 1 year were monitored.
Two participants died in the follow-up period, one in each trial arm. The cause of death of the NRT participant
was traumatic neck injury and that of the e-cigarette participant was ischaemic heart disease. There were
27 SAEs reported in the e-cigarette arm and 22 in the NRT arm (see Appendix 1, Table 34). None of the SAEs
were classed as related to study product use. There were six pulmonary events: five in the e-cigarette arm and
one in the NRT arm (not counting a hospitalisation concerning a lung mass in the NRT arm). The two participants
who were hospitalised with pneumonia were both smoking at the time (one was also vaping). The participant
in the e-cigarette arm who was hospitalised with asthma had recently stopped vaping and relapsed to smoking.
One of the participants with chronic obstructive pulmonary disease (COPD) exacerbation was smoking and
vaping at the time; e-cigarette use was not ascertained in the remaining case.
Adverse reactions
Table 18 shows the incidence of elicited ARs in the two trial arms that were reported at least once. NRT
caused more nausea, whereas e-cigarettes caused more throat/mouth irritation.
TABLE 14 Urges to smoke in abstainers at 1 and 4 weeks post TQDa
Urge to smoke
Trial arm at 1 week,
mean (SD)
t-test; p-value
Trial arm at 4 weeks,
mean (SD)
t-test; p-value
E-cigarette
(n= 158)
NRT
(n= 131)
E-cigarette
(n= 186)
NRT
(n= 132)
Frequency 2.5 (1.1) 2.8 (0.9) –3.1; 0.002 1.9 (0.9) 2.2 (0.8) –3.3; 0.001
Strength 2.7 (1.1) 3.2 (1.0) –3.6; 0.0004 2.1 (1.1) 2.4 (1.0) –2.6; 0.001
Composite urge score 2.6 (1.0) 3.0 (0.9) –3.6; 0.0003 2.0 (1.0) 2.3 (0.9) –3.1; 0.003
a 1 = not all all/no urges and 5 = all the time/extremely strong.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
TABLE 15 Urges to smoke at 1 and 4 weeks post TQD (whole sample)
Urge to smoke
Trial arm at 1 week,
mean (SD)
t-test; p-value
Trial arm at 4 weeks,
mean (SD)
t-test; p-value
E-cigarette
(n= 389)
NRT
(n= 383)
E-cigarette
(n= 365)
NRT
(n= 334)
Frequency 2.8 (0.05) 3.1 (0.05) –3.8; 0.0002 2.3 (0.06) 2.7 (0.06) –4.1; < 0.001
Strength 3.1 (0.06) 3.3 (0.05) –3.8; 0.0002 2.6 (0.06) 2.9 (0.06) –3.6; 0.0004
Composite urge score 2.9 (0.05) 3.2 (0.05) –4.2; < 0.001 2.4 (0.05) 2.8 (0.06) –4.1; 0.0001
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TABLE 16 Change from baseline in withdrawal symptoms among participants who were abstinent and provided
complete data
Withdrawal symptom
Trial arm, mean (SD)
t-value; p-valueE-cigarette (n= 158) NRT (n= 131)
1 week post TQD
Depressed 0.05 (0.7) 0.08 (.8) –0.3; 0.77
Irritable 0.27 (1.2) 0.78 (0.12) –3.4; 0.001
Restless 0.13 (1.1) 0.43 (1.5) –2.0; 0.05
Hungry 0.33 (1.1) 0.59 (1.3) –1.9; 0.06
Poor concentration –0.06 (0.8) 0.25 (1.2) –2.6; 0.009
Composite score 0.14 (0.58) 0.43 (0.75) –3.6; 0.001
4 weeks post TQD (n = 191) (n = 134)
Depressed –0.02 (0.8) –0.04 (0.9) –0.2; 0.86
Irritable –0.01 (0.1) 0.20 (1.1) –1.7; 0.09
Restless –0.13 (1.1) –0.08 (1.3) –0.3; 0.74
Hungry 0.19 (1.2) 0.31 (1.4) –0.8; 0.43
Poor concentration –0.15 (0.9) –0.04 (1.0) –1.0; 0.30
Composite score –0.01 (0.6) 0.08 (0.8) –1.3; 0.20
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
TABLE 17 Change from baseline in withdrawal symptoms among all participants
Withdrawal symptom
Trial arm, mean (SD)
t-value; p-valueE-cigarette (n= 389) NRT (n= 383)
1 week post TQD
Depressed 0.1 (0.1) 0.1 (0.1) –1.0; 0.30
Irritable 0.4 (0.1) 0.6 (0.1) –2.7; 0.008
Restless 0.1 (0.1) 0.4 (0.1) –2.8; 0.006
Hungry 0.3 (0.1) 0.5 (0.1) –2.6; 0.01
Poor concentration 0.1 (.01) 0.2 (0.1) –2.9; 0.004
Composite score 0.2 (0.1) 0.4 (0.1) –4.1; 0.0001
4 weeks post TQD (n = 364) (n = 334)
Depressed 0.12 (0.1) 0.13 (0.1) –0.2; 0.87
Irritable 0.11 (0.1) 0.24 (0.1) –1.5; 0.13
Restless –0.02 (0.1) 0.04 (0.1) –0.7; 0.51
Hungry 0.10 (0.1) 0.39 (0.1) –2.9; 0.004
Poor concentration –0.04 (0.1) 0.06 (0.1) –1.3; 0.18
Composite score 0.1 (0.04) 0.2 (0.04) –2.2; 0.03
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All three reactions (nausea, sleep disturbance and throat/mouth irritation) were mostly mild. Table 19 shows
the proportion of participants who rated these reactions as severe. The two trial arms did not differ in this respect.
Table 20 compares the two trial arms in terms of self-reported respiratory symptoms among participants
who provided relevant data. The p-value and odds ratio relate to the occurrence of respiratory symptoms
at 12 months, adjusted for the baseline symptoms occurrence and trial centre. Significantly more
participants in the e-cigarette arm than in the NRT arm stopped coughing and producing phlegm.
TABLE 18 Adverse reactions reported on at least one occasion
AR
Trial arm, n (%)
Relative risk (95% CI)bE-cigarette (N= 438) NRT (N= 446)
Nausea 137 (31) 169 (38) 0.83 (0.69 to 0.99)
Sleep disturbances 279 (64) 303 (68) 0.94 (0.986 to 1.04)
Throat/mouth irritationa 286 (65) 221 (51) 1.27 (1.13 to 1.43)
a Participants who tried patches only were excluded (n = 432).
b Logistic regression. ARs reported on at least one occasion from week 1 to 52 weeks post TQD regressed onto trial arm
with adjustment for study site.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
TABLE 19 Adverse reactions rated as severe
AR
Trial arm, n (%)
Relative risk (95% CI)aE-cigarette (N= 438) NRT (N= 446)
Nausea 29 (6.6) 29 (6.5) 1.02 (0.62 to 1.67)
Sleep disturbances 57 (13) 58 (13) 1.0 (0.71 to 1.4)
Throat/mouth irritationb 26 (5.9) 17 (3.8) 1.51 (0.84 to 2.74)
a Logistic regression. ARs reported on at least one occasion from week 1 to 52 weeks post TQD regressed onto trial arm
with adjustment for study site.
b Participants who tried only patches were excluded (n = 432).
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
TABLE 20 Baseline and 12-month respiratory symptoms
Respiratory symptom
Trial arm, n (%)
p-value Relative riska (95% CI)
E-cigarette (N= 315) NRT (N= 279)
Baseline 12 months Baseline 12 months
Shortness of breath 120 (38.1) 66 (21.0) 92 (33.0) 64 (22.9) 0.25 0.9 (0.7 to 1.1)
Wheezing 102 (32.4) 74 (23.5) 86 (30.8) 59 (21.2) 0.73 1.1 (0.8 to 1.4)
Cough 173 (54.9) 97 (30.8) 144 (51.6) 111 (39.8) 0.004 0.8 (0.6 to 0.9)
Phlegm 137 (43.5) 79 (25.1) 121 (43.4) 103 (36.9) 0.002 0.7 (0.6 to 0.9)
a Logistic regression with symptoms at 12 months regressed onto trial arm while adjusting for baseline scores and
trial centre.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
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To determine whether or not the better cough and phlegm outcomes in the e-cigarette arm participants
were a result of their higher quit rate, a non-planned exploratory analysis controlling for 1-year abstinence
status was run. This did not alter the results (RR = 0.8, 95% CI 0.6 to 0.9, p = 0.008, for cough; and
RR = 0.7, 95% CI 0.6 to 0.9, p = 0.004, for phlegm).
Discussion
Clear differences between the quit rates in the two trial arms emerged early on, with the participants
in the e-cigarette arm having significantly higher validated quit rates at all time points. Sustained
biochemically validated 1-year quit rate with NRT products of patient choice, including NRT combinations
and an opportunity to vary products, was 9.9%, tallying closely with success rates reported previously for
the UK SSSs 1-year validated outcome.25 In the e-cigarette arm, the quit rate was 18.0%. Participants in
the e-cigarette arm showed significantly better adherence and experienced fewer urges to smoke, and
reduced strength of urges, throughout the initial 4 weeks of their quit attempt than those in the NRT arm.
Participants assigned to e-cigarettes reported significantly less coughing and phlegm at 1 year than those
assigned to NRT.
In the following sections, key aspects of the trial and of its findings are discussed.
Sample representativeness
The trial sample comprised participants who are typical of clientele of UK SSSs: middle-aged smokers
unable to quit smoking unaided, including some 40% in receipt of free prescriptions (a marker of illness or
social disadvantage), with high baseline CO readings, who have tried a range of stop smoking aids before.
The findings are likely to be valid for clinical samples but may not be generalisable to smokers who are less
dependent or who try e-cigarettes for reasons other than quitting smoking.
Representativeness of the two interventions
In this pragmatic trial, e-cigarettes were used as they could be used in routine SSS practice, namely
smokers were provided with a starter kit and advised to purchase e-liquids with a flavour and nicotine
strength that they found helpful. They were also encouraged to buy a different e-cigarette model if
needed. A range of e-cigarette products and e-liquids are available for smokers with different needs and
the practise utilises the opportunity this provides. Participants who found e-cigarettes helpful had no
problem with purchasing their own supplies. In fact, by the end of the first 2 weeks of treatment, when
trial e-liquid was still available, most were already using e-liquids that they had purchased themselves.
This approach makes it probable that the results can be achieved in any setting that can replicate the trial
conditions, but it also means that the trial results may not be replicated if just one type of e-cigarette is
provided to all participants, especially if this is a weak cartridge-based product.
Nicotine replacement therapy was provided under generous conditions that are probably optimal for
treatment efficacy. The medication was provided free of charge, apart from the prescription charge
applicable at one trial site. Participants were encouraged to select from among the full range of NRT
preparations products that best fit their needs; most participants (88%) were provided with two forms
of NRT, usually a patch plus a fast-acting NRT formulation, and more than one-third of participants
experimented with different NRT products during the initial treatment period. NRT use was also supervised
by SSS clinicians trained in guiding clients and optimising NRT use.
Caution was taken to avoid possible bias related to product cost and effort needed to obtain it. At the
SSSs that provide NRT on LOR, participants in both groups had to collect NRT from a pharmacy, and the
e-cigarette group exchanged this for an e-cigarette at randomisation. Reassuringly, no participant listed
cost as the reason for discontinuing product use.
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Effect of e-cigarettes on smoking cessation
The only previous trial9 reported a small, non-significant, advantage of e-cigarettes over patches (7.3%
vs. 5.8% quit rates at 6 months). However, it used an early unreliable Cig-A-Like e-cigarette (Elusion™,
Auckland, New Zealand) with very low nicotine delivery (maximum concentration of 3 ng/ml, compared
with 18 ng/ml from cigarettes and 10 ng/ml from refillable e-cigarettes using 20 mg/ml e-liquid)27 and
the products were provided with no face-to-face support, which explains the low quit rates. In this trial,
e-cigarettes were significantly more effective than NRT at all time points, despite the fact that the number
of participants in the NRT arm who also used e-cigarettes was more than three times the number in the
e-cigarette arm who used NRT as well. Such ‘contamination’ could not exert much influence on the
primary outcome of abstinence from the third week of treatment onwards; at 3 weeks contamination was
low, but those who abstained for longer periods included abstainers in the NRT arm who quit with the
help of e-cigarettes, making the results conservative.
Product use at 1 year
Most abstainers in the e-cigarette arm (80%) were still vaping at 1 year, whereas only 9% of NRT arm
abstainers were still using NRT. Ongoing use of nicotine-containing products could be seen in both a positive
and negative light. Product use may assist with maintaining smoking abstinence and preventing relapse,
ameliorate the weight gain that typically follows nicotine withdrawal and provide some continuation of
the positive subjective effects that smokers used to get from smoking. However, it can be also a cause for
concern if overcoming nicotine addiction is seen as an important aim in itself, even if ongoing nicotine use
carries negligible health risks, or if ongoing vaping poses clear health risks.
Regarding continuous nicotine use, when NRT was first introduced, the view that combating nicotine
use is the main purpose of stop smoking interventions led to claims that someone who stopped smoking
successfully but still uses NRT should not be counted as a treatment success. However, the motivation
for helping smokers quit is to help them to avoid the health risks of smoking, and, once this rationale
became widely accepted, such concerns largely disappeared. The SSS sees its aim as helping smokers avoid
smoking-related disease and death, and there are no concerns about long-term use of NRT, especially as
such use prevents relapse in ex-smokers with high tobacco dependence and other negative prognostic
signs.28 However, the concerns about ongoing nicotine use are likely to re-emerge as smokers switch to
vaping. For those who are concerned about nicotine use per se, some reassurance is provided by data
showing that vapers show lower dependence on e-cigarettes than on cigarettes,29,30 and smokers who
successfully stop smoking with the help of e-cigarettes tend to eventually stop vaping as well.10 It is
currently estimated that the health risks of long-term vaping are unlikely to exceed 5% of the risks of
smoking.2 Some risks may yet emerge and ongoing monitoring is needed, but no health risks from
e-cigarettes used for up to 1.5 years have been identified to date, and biomarkers of risk that have been
examined so far show that long-term vapers do not differ from long-term NRT users (and probably also
from non-smokers).31
Product adherence and attractiveness
Among participants who engaged with treatment, adherence was initially high in both trial arms. The
difference in adherence to the two products increased markedly over time, with participants being much
more likely to continue with e-cigarette use than with NRT use at later follow-ups. This could be related
to the fact that NRTs are presented as a medicinal product with an expectation of time-limited use,
whereas e-cigarettes are a consumer product that is more easily accessible and not linked to expectations
of short-term use only. However, satisfaction with the product may have been the most important factor
as suggested by other data on product differences. Unsatisfactory taste, lack of satisfaction and ARs were
the main reasons for stopping NRT use and were more frequent in the NRT trial arm than in the e-cigarette
trial arm. E-cigarettes were also rated as significantly more helpful, more similar to cigarettes in taste and
more satisfying than NRT.
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It is possible that, apart from better sensory effects, e-cigarettes were also providing better tailored nicotine
replacement than NRT. Allowing participants to select their own e-liquid could have provided better dose
tailoring than NRT products allow. It is paradoxical that smokers can select their nicotine levels freely while
they smoke, but once they enter NRT treatment this autonomy is removed and nicotine dosing is placed in
the hands of those who treat them. In addition, NRT products are formulated to provide very low nicotine
doses, far below what smokers normally obtain from their cigarettes. Using NRT combinations could ameliorate
this problem, but the short-acting products added to patches are typically used only opportunistically.
Future studies should collect cotinine samples to allow comparisons of the actual nicotine intake.
E-cigarette and nicotine replacement therapy products used
The starter pack consisted of a refillable (tank) e-cigarette. Very few users switched to cartridge-based
products. This corresponds to data showing that e-cigarette users prefer refillable e-cigarettes5 and that
these provide higher nicotine levels,32 better relief from craving and higher satisfaction33 than Cig-A-Like
products. Vapers tried a wide range of e-liquid flavours. Fruit flavours were the most popular, with tobacco
flavour also popular at 6 months but less so at 1 year. Sweet flavours (chocolate, candy) and menthol
increased in popularity over time. This corresponds with data showing that fruit flavours are the most
popular, with many smokers also liking candy flavours.5 NRT product choices were similar to those observed
across SSSs.34 The patch was by far the most popular choice, followed by the inhalator and mouth spray.
Effects of the two treatments on withdrawal symptoms
Participants using e-cigarettes reported significantly lower intensity and frequency of urges to smoke than
participants using NRT throughout the initial treatment period. All existing stop smoking medications are
assumed to exert their main therapeutic effect via craving reduction, and this is likely to be the case with
e-cigarettes too. Most other tobacco withdrawal symptoms were also lower in the e-cigarette arm than in
the NRT arm during the first week of abstinence, although this effect subsided by 4 weeks, when most
withdrawal symptoms in continued abstainers reduced to almost zero.
Product safety
There was one death in each trial arm. A difference in frequency of acute pulmonary events was noted
(five in the e-cigarette arm vs. one in the NRT arm, or two if counting a lung mass in the NRT arm). Two of
the e-cigarette-arm participants with pulmonary SAEs were not vaping at the time, two were vaping and
smoking, and the vaping status of one is not known. The difference is likely to be due to chance; however,
the study design did not set out to examine e-cigarette safety. Future study designs should include more
reliable evaluation of any possible pulmonary risks of vaping.
Sleep disturbance was monitored, as this is considered to be an AE that is commonly associated with the use
of NRT patches, but sleep disturbance was equally common in both trial arms. As expected, throat/mouth
irritation was more frequently noted by e-cigarette users and nausea was reported more frequently by NRT
users, but both effects were mostly mild. The two groups did not differ in the incidence of severe reactions.
Contrary to general expectations, e-cigarette use seemed to have a significantly positive impact on elicited
respiratory symptoms. Previous findings on this have been contradictory. Studies of cells and animals have
suggested that vaping may result in respiratory infections;35,36 however, a large internet survey of vapers
found that the switch from smoking to vaping was accompanied by reduction in respiratory infections.37
It was proposed that this could be because of the antibacterial properties of propylene glycol, which is usually
one of the constituents of e-liquid. Respiratory symptoms were monitored to see if vaping has any negative
or positive effects. Changes in wheezing and shortness of breath did not differ between the two arms,
but there was a significant difference in two other symptoms that are more closely linked to respiratory
infections: cough and generating phlegm. There was improvement in both study arms compared to baseline,
but the improvement in the e-cigarette arm was significantly larger. Importantly, the effects were not due
to the higher quit rate in the e-cigarette arm, and so they support the hypothesis suggested by previous
observations that vaping provides protection against respiratory tract infections. Future studies should include
objective measures of lung health and respiratory symptoms.
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Economic analysis
The full economic analysis is presented in Chapter 5, but, in summary, compared with NRT intervention,
e-cigarette intervention was less costly and generated higher quit rates; therefore, it was also more
cost-effective. There was an indication that the e-cigarette arm achieved a higher quality-adjusted life-year
(QALY) gain than the NRT arm during the 12-month period, but the difference was not significant. The
e-cigarette intervention did not appear to lead to an increase in spending on cessation aids on the
smokers’ part while reducing the costs to the smoking cessation services.
Trial limitations
One obvious limitation of open-label trials is the possible effect of expectations. There is no evidence that
expectations can boost long-term abstinence rates, but it is likely that they can lower the quit rate in the
condition that is seen as inferior, for example if therapists communicate low expectations and/or patients
think that they have received the short straw they may drop out of treatment or not put as much effort
into quitting. This trial was presented as testing whether or not e-cigarettes are as effective as NRT to
avoid creating expectations of its superiority. It was also possible to check whether or not a depressed
quitting in the NRT condition contributed to the trial results. A study25 of the long-term quit rates among
a group of SSSs with above average early outcomes, using the same outcome criteria as this trial, showed
an overall validated 1-year quit rate of 8%. Clients receiving identical individual treatment as used in this
trial, provided by specialist advisors, had a quit rate of 10%. However, 46% were treated with varenicline,
which was associated with significantly higher abstinence than NRT (12% vs. 7%, respectively). A large
RCT38 has recently confirmed the superiority of varenicline over other medications. Thus, it is reassuring
that the NRT-arm quit rate (10%) was commensurate with or superior to the standard outcome in this
treatment setting.
We tried to make treatment access similar in the two trial arms, but all e-cigarette users had to pay for
their supplies, whereas only about half of NRT users had to pay prescription charges. However, this is
unlikely to play a major role, as cost was not listed among the important reasons for discontinuing product
use by either trial arm.
The 79% follow-up rate at 1 year was comparable with the 78% follow-up rate achieved in another
recent NIHR-funded trial in the same setting and population,39 79% achieved in SSS service evaluation25
and 75% in an earlier trial that also took place within SSSs.40 The follow-up rate was somewhat lower in
the NRT arm (77% for NRT vs. 81% for e-cigarettes), which probably reflects the fact that unsuccessful
quitters are more likely to drop out. Delivering higher rates of follow-up in this population is difficult.
Smokers receiving face-to-face support usually feel embarrassed if they do not succeed, and avoid further
contact. However, incomplete data are another trial limitation.
Participants’ weight was not monitored, nor were participants asked about weight changes that they
experienced. As evidence is emerging that e-cigarette use may ameliorate post-cessation weight gain,
future studies should include such monitoring.
As discussed in Sample representativeness, the trial sample comprised dependent smokers seeking
treatment, and they received instructions, support and monitoring of their progress. The results may not be
generalisable to other types of smokers and other settings. The trial did not evaluate any one particular
e-cigarette product, but the choice of e-cigarette devices and e-liquids that smokers can access currently
in the UK. Practically all e-cigarette arm participants used refillable e-cigarettes. The results may not apply
to the now largely obsolete Cig-A-Like e-cigarette (now produced almost exclusively by the tobacco
industry) or to settings and countries that only allow one particular e-cigarette product.
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Implications for health care
Stop Smoking Services have become more receptive to e-cigarettes over the past few years and most now
condone or encourage e-cigarette use, but only a few provide e-cigarette starter packs. The reluctance to
do so is understandable, because evidence of the comparative efficacy of e-cigarettes is limited to one
trial9 showing that early e-cigarettes matched NRT patches when used with minimal support. The results of
the current trial are likely to change the current practice. The trial provides evidence that e-cigarettes not
only match but surpass the efficacy of NRT, even when combination NRT is provided alongside expert
advice and supervision.
The adoption of e-cigarettes by SSSs could generate several benefits. It is likely that e-cigarettes as a
smoking cessation tool are more effective if accompanied by support and monitoring, as has been shown
for NRT.41 If smokers switching to e-cigarettes do so with SSS support, they are likely to improve their
chance of successfully stopping smoking. The offer of e-cigarette starter packs could be particularly
attractive to disadvantaged smokers, thus improving the service reach in areas where it is most needed.
Offering e-cigarettes as one of the treatment options would also make the services more economical.
The full course of a single NRT product is typically > £100 and combinations of two NRT products, widely
used by SSSs, cost even more. The more advanced starter pack used in this trial cost £30. If SSSs start
to provide e-cigarettes, this may also counteract some of the antivaping reporting in UK tabloids and
contribute to dispelling the worrying increase among smokers of a belief that e-cigarettes are as dangerous
as cigarettes.2
Outside clinical settings, the trial results reinforce the general recommendation to smokers to use e-cigarettes
to stop smoking as provided by, for example, Stoptober, the Royal College of Physicians and the National
Centre for Smoking Cessation and Training. The effects of e-cigarettes without multisession support may
well be lower, but there are currently > 1.5 million people in the UK who report that they stopped smoking
with the help of e-cigarettes.
The trial is likely to have an international impact, but different countries have different e-cigarette
regulations and different attitudes to ‘harm reduction’. We believe that, in this context, if e-cigarettes
help smokers who seek treatment to stop smoking, then they should not be seen as a method of harm
reduction but as a method of smoking cessation. A small proportion of such smokers are likely to use
e-cigarettes in the long term, but the majority will use e-cigarettes only temporarily, over a period of time
that is assumed to carry no health risk. The ultimate goal is to remove any health risks altogether and help
people who wish to stop all nicotine use to do so, but extended nicotine use can be helpful to smokers
who struggle to stop smoking otherwise. Health professionals could now inform dependent smokers that
e-cigarettes are superior to NRT as a method of stopping smoking.
Recommendations for research
Longer-term follow-ups of smokers quitting with the help of e-cigarettes and smokers quitting with other
methods are needed to establish the frequency of long-term e-cigarette use in this population and any health
effects that such use may have. These results also suggest an intriguing possibility that e-cigarette use may
reduce respiratory infections, but it may also have some adverse effects. Studies of medical records and lung
function in ex-smokers quitting with and without e-cigarettes are needed to clarify this issue.
A combination of varenicline with NRT has not generated clear additional effects,42 but a combination
of varenicline and e-cigarettes could hold more promise. Adding a more satisfactory sensorimotor
replacement to varenicline could, in theory, improve withdrawal relief and lower the risk of relapse.
There may also be smokers who have only limited reaction to one of the treatments but are sensitive
to the other; the combination may be of particular benefit to this group.
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A replication of this finding is also needed. Most e-cigarette studies that we are aware of plan to compare
e-cigarettes with nicotine and e-cigarettes without nicotine. Such studies follow the standard approach for
testing drugs, but this does not seem to be a productive paradigm in this field. The objective of these
studies is unclear. E-cigarettes without nicotine are rarely used and so there is no practical need to evaluate
them. If the objective is to determine whether or not giving smokers nicotine helps with quitting, there are
already > 100 RCTs showing that it does.19 Such studies will provide no information on the main reason
that e-cigarettes are much more popular than other forms of NRT, namely the combination of nicotine and
sensorimotor input.43
Population data suggest that e-cigarettes help many smokers quit smoking without any input from
health-care professionals. It is not known to what degree an intensive support, such as that provided
in this trial, increases e-cigarette efficacy. Studies that compare quit rates of e-cigarettes provided
alongside differing degrees of support are needed. This would help to establish if public health messages
should focus on encouraging the switch from smoking to vaping within stop smoking services, or on
recommending switching to vaping without such need.
Conclusion
Within the context of multisession treatment for smokers seeking help, as provided by the UK specialist
SSS, e-cigarettes were significantly more effective than NRT. The provision of e-cigarette starter packs by
specialist SSSs may help to improve the treatment efficacy, cost efficacy and reach of SSSs.
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Chapter 5 Economic evaluation of the TEC trial
Methods
The economic evaluation was conducted by way of a cost-effectiveness analysis. Following NICE
guidance,44 the analysis was performed from the NHS and Personal Social Services (PSS) perspective to
reflect the NHS England decision-making framework. The analysis was also conducted from a wider
perspective to explore the possible societal impact of the intervention. All costs are presented in 2015/16
Great British pounds. The objectives of the analysis were to:
1. assess the cost-effectiveness of e-cigarettes over and above usual care at the 12-month follow-up
(i.e. the primary outcome)
2. estimate the potential long term cost-effectiveness of the intervention.
These objectives were achieved by combining data collected within the trial and existing models.
Intervention training cost
Because e-cigarettes are a relatively new product to the NHS, SSS advisors in their official capacity are
provided with additional training on how to use the product before they can confidently provide smokers
with advice about the product. The training was estimated to take 1 hour and was delivered once for each
site by two of the research team members. A total of 30 advisors or researchers attended the training.
Although they provided support for the participants in both arms, this training was specific to the e-cigarette
intervention. Each was equipped with one demonstration kit at a cost of £19.35, including liquid and
accessories. To reflect routine practice should the intervention be rolled out, all of the attendees were costed
as advisors, which was the average of NHS pay band 5 and 6. Trainers were costed at NHS pay band 6.
Including salary oncosts, overheads and capital, the cost was estimated at £37 per hour for advisors and £42
per hour for trainers.45
Intervention delivery cost
The intervention had two components. The first was behavioural support and the second was the provision
of a smoking cessation aid. Behavioural support was the same for both arms. It was delivered by the NHS
SSS advisors or researchers in a face-to-face setting or by telephone, with one session prior to the TQD
followed by one session on the TQD and four weekly sessions after the TQD.
The smoking cessation aid for the e-cigarette arm was the e-cigarette. The research team provided a
starter kit (i.e. a 2-week supply) to the participants free of charge. A further 2-week supply of e-liquid
could be requested if the participants failed to purchase their own at 2 weeks post TQD. Participants were
also provided with a printed information sheet on how to use the e-cigarette.
The smoking cessation aid for the NRT arm was a NRT product. Owing to the different settings in the trial
sites, NRT products were provided to the participants either directly or through a LOR. Direct provision
of NRT was free of charge. However, LOR requires participants to go to a pharmacy and redeem the
prescription. A prescription charge of £8.20 per item might be payable if the participant was not otherwise
exempted.46 These NRT products were provided for 4 weeks on a fortnightly basis. Further supply could be
requested on completion of the treatment. The participants were also provided with a printed list of local
pharmacies.
The form and dosage of NRT was matched to all the products with the same chemical name, dosage and
form in Prescription Cost Analysis – England 201647 to get the weighted average cost per item of each
NRT product. Where the information on some aspects was missing (e.g. patches with no dosage recorded),
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the weighted average cost based on available information was applied. The dispensing fee per item was
estimated based on the data published by the NHS Business Services Authorities.48 Owing to different
approaches of dispensing NRT products between the research sites (direct dispense vs. LOR), a conservative
assumption was made that once an LOR is provided, the stated NRT products are considered dispensed.
This is to avoid underestimating cost to the NHS.
The usage of behavioural support, NRT products and/or e-cigarettes was recorded in the CRF at each
support session. The cost of printing the e-cigarette leaflets and a pharmacy list was recorded by the
research team.
Smoking cessation service outside the intervention period
Utilisation of smoking cessation services outside the intervention period, including pharmacotherapies and
e-cigarettes, was recorded at baseline and at the 6- and 12-month follow-ups by self-report. Each covered
the services utilisation in the six-month period before data collection. The quantities reported were then
multiplied by the unit costs of corresponding services or net ingredient cost plus dispensing fee of
prescribed items using secondary data sources (see Appendix 1, Table 35).
Health-care service use
Health-care and social services use data were collected at baseline and at the 6- and 12-month follow-ups.
The quantities of the service use were collected using a self-report questionnaire. The quantities were then
multiplied by a set of weighted national average costs following standard health economics methodology
(see Appendix 1, Table 35).
Quality of life
Health-related quality of life was measured using the EQ-5D-5L.49 By applying the UK population tariff to
the scores of five domains of EQ-5D-5L, a utility score was to be calculated at different time points. QALYs
were then derived by calculating the area under the curve from baseline to 6 months and from 6 months
to 12 months.18 In addition, EuroQol Visual Analogue Scale (EQ VAS) results were also collected at the
three time points.
At the time of the analysis, NICE had issued a statement recommending mapping the EQ-5D-5L descriptive
system data onto the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), valuation set, despite the
valuation set for EQ-5D-5L being made available earlier.50 Therefore, although the quality-of-life data were
collected using the EQ-5D-5L, the valuation of utility scores was conducted using the recommended
mapping function.51
Analysis
Missing data
The primary analysis was conducted on an intention-to-treat basis. For the smoking cessation service use
outside the intervention and health-care service use, data were classified as missing when all sections
under one question were left blank. For instance, if one question had five subquestions [annotated as a),
b), c), etc.], then all five were deemed missing when all five were left blank. If one part was answered,
the others were assumed as zero. In the case of the EQ-5D-5L, owing to the structure of the questionnaire,
the whole section was considered missing if any of the five questions was not answered. Missing data due
to death would result in all costs and QALYs being equal to zero at the time points after the date of death.
Missing data were handled by multiple imputation following Rubin’s rules,52 assuming that any missing
data were missing at random. A chained equation model was developed and predictive mean matching
by arms was used as the imputation method, using the 10 nearest neighbours to the prediction as a set to
draw from.
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The imputation model included training costs, intervention delivery costs, smoking cessation help costs at
baseline and at 6 and 12 months, pharmacotherapies at baseline and at 6 and 12 months and health-care
service use costs, EQ VAS scores and utility scores at baseline and at 6 and 12 months, age, sex, trial site,
FTCD at baseline, ethnicity and entitlement to free prescriptions. Although not a cost to the NHS, the costs
of NRT products purchased over the counter (OTC), the costs of e-cigarette purchases and prescription
charges, when applicable, were also included in the imputation model.
The EQ-5D-5L results were imputed at the utility score level rather than at the individual domain level.
Owing to the arrangement of the questionnaire, the costs of service use were imputed at an aggregated
level as smoking cessation services, pharmacotherapies and health-care services, rather than at an
individual service level. Training costs and intervention delivery costs were imputed as individual variables,
as their costing methods were different. As a rule of thumb, the number of imputations was set to
approximately the highest percentage of missing data in all variables.53
Primary analysis
The primary analysis took the form of an incremental cost-effectiveness analysis. The costs included
intervention costs, smoking cessation service cost after the intervention period and health-care service use
cost that had occurred during the 12-month period. The difference in costs between arms was controlled
for smoking cessation service costs and health-care service use at baseline, age, sex, trial site, entitlement to
free prescriptions and baseline FTCD. The QALYs were calculated during the same time period. The difference
in QALYs between arms was controlled for utility value at baseline, age, sex, trial site, entitlement to free
prescriptions and baseline FTCD. Combining both, an ICER of cost per QALY was calculated to assess the
cost-effectiveness of e-cigarettes, compared with NRT. The ICER was then compared with the national WTP
threshold of £20,000–30,000 per QALY gained.44
Sensitivity analysis
A non-parametric bootstrap resampling technique was used to assess the uncertainty surrounding the ICER.
Bootstrapping has been proposed as an efficient approach for calculating the confidence limits for the ICER,
as its validity does not depend on any specific form of underlying distribution.54–57 A cost-effectiveness plane
(CEP) and a CEAC were plotted, based on the outcomes of 5000 bootstrap iterations, to illustrate the
uncertainty.58
To assess the impact of the missing data, an additional set of analyses were carried out using the CCA,
analysing results only for those participants for whom both the completed cost and outcome data were
available at all time points.59–62
Secondary analyses
Comparison of weekly nicotine replacement therapy dispense with nicotine replacement
therapy use
A separate analysis was carried out to examine the potential impact on the intervention costs of the
assumption of NRT dispense equating NRT use. In the primary analysis, the NRT costs were estimated
based on the dispensing records in the NRT arm. The dispensing records reflected the NRT dispensed for
the week following the session from the TQD. From 1 week post TQD, participants in the NRT arm also
reported their use of NRT in the week before the session. The selection of NRT products was the same as
for the dispensing records; therefore, the same set of weighted average costs per unit of NRT products
as used in the primary analysis was applied. The method employed provided a conservative estimate,
as it was possible that not all products used were provided by the trial. In the case of obtaining the NRT
products OTC, the actual costs to the participants could be higher than our estimates. Lacking means to
distinguish the sources of self-reported NRT products, the net ingredient cost plus dispensing fee was used.
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The estimated weekly cost of NRT used in the past week was then compared with the estimated weekly
cost of recorded NRT dispensing in the previous session among the participants for whom both were
recorded.
Costs of smoking cessation aids to the NHS and participants’ expenses on
smoking cessation
As e-cigarettes are not currently provided by the NHS, and NRT products might be purchased OTC outside
the intervention period, excluding participants’ expenses on e-cigarettes and OTC NRT products might
lead to a conclusion of cost-effectiveness by shifting the costs to the participants. To assess this possibility,
the costs of purchasing e-cigarettes (including refills) and NRTs OTC, and prescription charges for redeeming
the pharmacotherapies when applicable, were included to compare the distribution of smoking cessation
aids costs between the NHS and the participants in both arms. The costs of OTC NRTs were estimated
using the same set of net ingredient cost plus dispensing fee (see Appendix 1, Table 35).
In reality, the unit costs of NRT products purchased OTC are different from the ones in Table 35 (see
Appendix 1). However, given the complexity of the marketing sizes and prices and the lack of detailed
information on the products purchased, the same unit costs were used for the OTC products. It should be
noted that the actual expenses could, therefore, be higher than these estimates. The cost of e-cigarettes
(including refills) was estimated based on self-report by the participants who answered the question ‘How
much money have you spent on e-cigarette products in the last 6 months?’.
Long-term cost and outcome projections
Smoking has been found to present an increased risk of developing many diseases, such as cancer, COPD
and cardiovascular disease.63,64 The relationship between smoking and life expectancy has been proven by
the British Doctors’ Study using data collected over 5 decades.65 The study found that smokers who quit
smoking at ages 30, 40, 50 and 60 gained 10, 9, 6 and 3 years of life, respectively. Smoking cessation,
therefore, has impacts on both the costs of treating smoking-related diseases and health-related quality of
life over people’s lifetime.
The NICE guidance to the methods of technology appraisal44 recommends that the time horizon for
estimating cost-effectiveness should be sufficiently long to reflect important differences in costs and
outcomes between the interventions being compared. Therefore, in addition to the within-trial cost-
effectiveness analysis, a decision-analytic model was used to capture the lifetime cost-effectiveness of
the use of e-cigarettes, in comparison with NRT, when used within the UK SSSs.
Model structure
A Markov model was developed to estimate long-term costs and consequences of smoking cessation
interventions in this research team’s previous study.66 The Markov model is considered to be the most
appropriate approach to modelling smoking cessation, in which, over time, events such as quitting and
relapse recur.67 Smokers could quit their smoking habit with or without help, and former smokers may
relapse for various reasons.68 In this report, this model was populated with the costs and smoking status
during the trial period of the current trial and other updated parameters from a variety of sources.
The Markov model structure and the health-state transitions are demonstrated in Figure 3. This model
comprises three Markov states: current smoker, ex-smoker (former smoker/quitter) and death. The model
assumes a hypothetical cohort of 1000 individuals who are current smokers when entering the model, and
simulates events from there. Trial data were used to populate the first 12 months, for which the costs and
QALYs were estimated based on the trial for e-cigarettes and NRT, respectively. At the end of the first year,
individuals’ smoking status was assigned in proportion to the 12-month abstinence rates estimated from
the trial outcomes in each intervention group. Subsequently, individuals transferred between the three
states following the direction of the arrows with a model cycle of 1 year until the survivors completed their
90th year. The assumption was made that the individuals would not take the interventions again after the
trial period.
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The movement of individuals between health states at the end of each cycle was parameterised by
transition probabilities. Each health state is associated with a smoking-related health-care cost and health
benefit in terms of QALYs gained. The accumulated lifetime smoking-related health-care costs and QALY
gains for each intervention were computed by summarising values of all the individuals over all model
cycles. Both costs and QALYs were discounted at an annual rate of 3.5%.44 The model was programmed
in Microsoft Excel® 2016 (Microsoft Corporation, Redmond, WA, USA).
Model parameter inputs
To populate the model, comprehensive literature reviews were undertaken. The parameter values derived
from the literature and the sources are presented in Table 36 (see Appendix 1). Additional parameters
estimated from the trial data are presented in Results.
Relapse
It is common for people who achieved abstinence to smoke again. A systematic review and meta-analysis
conducted by Hughes et al.68 reported that the average 1-year relapse rate to smoking after 1 year of
abstinence was ≈10%. There is also evidence from retrospective studies that abstinence tends to become
stable after 10 years.69,70 Therefore, in this model we assumed that the risk of relapse for participants
reporting successful quit was 10% per year for the first 10 years and 0% thereafter.
Mortality
In the Markov model, all pathways eventually lead to death. The mortality rates for the first 12 months of the
model were derived from the number of participants who died during the trial period. From the second cycle
onwards, we first obtained mortality rates for people of different age and sex from the deaths registered
in England and Wales in 2016.71 We then took into account the increased risk of death for smokers and
ex-smokers compared with never-smokers reported by Doll et al.65 The estimated mortality rates for both
smokers and ex-smokers by age and sex are listed in Appendix 1, Table 36.
Utility
To estimate QALY gains for the two interventions, we need to attach utilities to the different health states
in the model. The QALYs estimated from the trial were used as the outcome input for the first cycle of the
model. For the period beyond the trial follow-up, the QALY data were derived from a study in England
conducted by Vogl et al.72 using data from the 2006 Health Survey for England.73 The estimates from this
study were considered representative as it had a large sample size of 13,241 and the survey participants
were chosen at random from all the addresses in England. The study estimated the utility values, measured
by EQ-5D based on age, sex and smoking status. Appendix 1, Table 36, summarises the average yearly
QALY gain for both smokers and ex-smokers by age group and sex.
Smoker
Death
Ex-smoker
FIGURE 3 The structure of the Markov model for long-term projection.
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Costs
The within-trial costs of the two interventions, consisting of both intervention costs and wider healthcare
resource use costs, were included in the model as a one-off cost for the first 12 months.
The long-term costs for treating smoking-related diseases for smokers and ex-smokers were measured
using cost-of-illness methods recommended by the World Health Organization Economics of Tobacco
Toolkit.74 The Hospital Episode Statistics (HES) records all the hospital inpatient care utilisation for patients
at NHS hospitals in England by diagnosis, sex and age.75 By combining the usage of admitted patient care
caused by 52 identified smoking-related diseases extracted from the HES data and the national average
unit costs extracted from the NHS reference costs, we estimated the annual costs related to smoking in
England by sex and age group.75–77 Because the NHS reference costs report the average unit cost at the
level of Healthcare Resource Group, we employed the NHS Code to Group Workbook (HRG4+)78 to link the
HES hospital episodes and reference costs. The smoking-attributable proportion was calculated as follows:
pcur (rcur − 1) + pex(rex − 1)
1 + pcur (rcur − 1) + pex(rex − 1)
, (1)
where pcur/pex is the proportion of current smokers/ex-smokers and rcur/rex is relative risk for having certain
smoking-related diseases for current smokers/ex-smokers compared with people who never smoked.
The estimated annual costs were then multiplied by the smoking-attributable proportion to generate the
costs attributable to smoking for smokers and ex-smokers. The results are summarised in Appendix 1,
Table 36.
Cost-effectiveness analysis and probabilistic sensitivity analysis
The Markov model was run separately for each intervention and yielded expected costs and effectiveness
in terms of QALYs. Similar to the within-trial economic evaluation, an incremental cost-effectiveness
analysis was conducted. The ICERs were calculated and the intervention with an ICER of < £20,000 per
QALY was considered as cost-effective, following NICE’s guideline.44
A probabilistic sensitivity analysis was performed to propagate the probabilistic uncertainty surrounding
each model parameter and estimate 95% CIs around the cost-effectiveness results. The model was
probabilistic in that all parameters were assigned probability distributions to reflect their sample variability.
Beta distribution was used for probabilities and a gamma distribution was used for costs and QALYs.67
Monte Carlo simulation was employed to draw a randomly selected estimate of each model parameter
from the assigned distribution, and the expected costs and QALYs for each intervention were calculated
using a particular combination of parameter values.79 This random draw was then repeated 10,000 times,
and the results of these simulations were reported in the form of the CEP and CEACs.
Results
In total, 886 participants were randomised: 447 in the NRT arm and 439 in the e-cigarette arm. There was
one death before the 6-month follow-up in the NRT arm and one death before the 12-month follow-up in
the e-cigarette arm.
Intervention training cost
The cost of trainees’ time for 1 hour of training was calculated by multiplying the number of advisors by
the hourly cost. It was recorded as £1110 in total. Additional training was delivered in three sites by two
trainers, resulting in £252 of trainer time cost. For each advisor to have a demo kit required the purchase
of 30 kits at a cost of £580.50. A training cost of £4.40 per participant was allocated to the e-cigarette
arm. There was zero training cost in the NRT arm.
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Intervention delivery cost
Behavioural support sessions
The mean number of sessions received was 5.5 (SD 1.0) in the e-cigarette arm and 5.2 (SD 1.2) in the
NRT arm, with a range of 2–6 sessions. In the NRT arm (n = 447), 62% of participants had six sessions,
15% had five sessions, 11% had four sessions, 6% had three sessions and 6% had two sessions. In the
e-cigarette arm (n = 439), 70% of the participants had six sessions, 15% had five sessions, 7% had
four sessions, 5% had three sessions and 3% had two sessions. The proportion of participants who had
six sessions was higher in the e-cigarette arm than in the NRT arm (70% vs. 62%).
On average, sessions 1 and 2 each lasted for 30 minutes. The subsequent sessions took approximately
15–25 minutes. For costing purposes, the middle point of the time estimate, 20 minutes per session, was
used for sessions 3–6. The cost of behavioural support was, therefore, £80 (SD £12) per participant in the
e-cigarette arm and £77 (SD £15) per participant in the NRT arm.
Nicotine replacement therapy/e-cigarette
The e-cigarette starter pack used in the trial was the One Kit, costing £19.35 per kit, including liquid and
accessories. During the trial, more had to be purchased because of breakages. The original version of
One Kit was no longer manufactured; instead, the newer version, One Kit 2016, was purchased at a cost
of £30.54 per kit including liquid and accessories. Overall, 396 participants were provided with the old
version and 42 were provided with the new version. One participant in the e-cigarette arm did not
accept the pack. The total cost of the e-cigarette starter packs, therefore, was £8945.28. There were
30 participants who were also given an extra bottle (10 ml) at around 2 weeks post TQD. At a cost of
£1.34 per bottle, that led to a total of £40.20. Therefore, the mean cost of e-cigarettes per participant in
the e-cigarette arm was £20 (SD £4).
Selected NRT products included nicotine patch, gum, microtab, mouth strip, lozenge, nasal spray, inhalator
and mouth spray. Table 37 in Appendix 1 presents the details of the products dispensed and their cost per
item, extracted from the Prescription Cost Analysis – England 2016,47 plus dispensing fee per item.48
The participants in the NRT arm were provided with a maximum of two NRT products. At TQD, 49 participants
had been provided with one product, 394 participants were provided with two and four did not receive any
NRT product. After the TQD, the number of participants who did not receive any product increased to 166 at
1 week post TQD, then dropped slightly to 149 at 2 weeks, remaining unchanged at 3 weeks and 4 weeks
post TQD. Post TQD, the number of participants who missed the sessions entirely was 53 at 1 week, 89 at
2 weeks, 120 at 3 weeks and 91 at 4 weeks. The number of participants provided with two products reduced
by two-thirds (to 121 at 1 week, 101 at 2 and 3 weeks and 117 at 4 weeks post TQD), whereas the number
of participants provided with one product increased (to 107 at 1 week, then 108 at 2 weeks, 77 at 3 weeks
and 90 at 4 weeks post TQD).
The 24-hour patch (21 mg) and 16-hour patch (25 mg) were the most popular products from TQD to
4 weeks post TQD, whether used alone or in combination with another product (Figures 4–8).
On the TQD, single use of nicotine inhalator and mouth spray was higher than use of the nicotine patch,
accounting for 2% and 3% of the participants who were provided with NRT, respectively. However, from
1 week to 4 weeks post TQD the 24-hour patch (21 mg) and 16-hour patch (25 mg) became much more
popular for single NRT use. For dual NRT use, the most popular combination among the participants who
were provided with NRT was nicotine inhalator in combination with either 24-hour patch (21 mg) or
16-hour patch (25 mg), followed by mouth spray in combination with either patch.
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FIGURE 4 Proportion of NRT dispensed on TQD in the NRT arm (n= 443).
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FIGURE 5 Proportion of NRT dispensed at 1 week post TQD in the NRT arm (n= 228).
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Single NRT – 16-hour
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16%
FIGURE 6 Proportion of NRT dispensed at 2 weeks post TQD in the NRT arm (n= 209).
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Information sheets for the use of the e-cigarette costed £37.50 in total, which was £0.09 per participant.
LOR was used in one of the three sites for NRT. A LOR cost £0.01 each and the total number issued was
732 in the NRT arm from TQD to 4 weeks post TQD. The printing cost of the pharmacy list for the NRT
arm was £23.70, which was £0.05 per participant.
In total, the mean intervention delivery cost was £201 (SD £77) per participant in the NRT arm and £100
(£13) in the e-cigarette arm (Table 21). The mean intervention delivery cost in the e-cigarette arm had a
bigger SD because of the variation of NRT provided to each participant.
Dual NRT – other
34%
Single NRT – other
19%
Other
44%
16-hour patch
(25 mg) +
inhalator
6%
24-hour patch (21 mg) +
mouth spray
6%
24-hour patch (21 mg) +
inhalator
10%
Single NRT – 24-hour
patch (21 mg)
14%
Single NRT – 16-hour
patch (25 mg)
11%
FIGURE 7 Proportion of NRT dispensed at 3 weeks post TQD in the NRT arm (n= 178).
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Single NRT – 24-hour
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11%
Single NRT – 16-hour
patch (25 mg)
10%
FIGURE 8 Proportion of NRT dispensed at 4 weeks post TQD in the NRT arm (n= 207).
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Smoking cessation services outside the intervention period
Outside the intervention period, the use of smoking cessation services was recorded at baseline and at
6 and 12 months. It consisted of smoking cessation help from general practitioners (GPs), NHS SSS and
NHS Smoking Helpline service. The use of smoking cessation services was low, on average, in both arms
(Table 22). In comparison with the mean values, the SDs appear to be bigger, indicating a small group of
participants with high usage of services.
Outside the intervention period, the use of pharmacotherapies/e-cigarettes was also reported at baseline and
at 6 and 12 months. All randomised participants reported these uses at baseline. Out of 447 participants in
the NRT arm, 60 reported use of NRT products, 57 reported use of e-cigarettes, 19 reported use of varenicline
and only one reported use of bupropion. Out of 439 participants in the e-cigarette arm, 47 participants
reported use of NRT products, 61 reported use of e-cigarettes, 10 reported use of varenicline and one
reported use of bupropion. At 6- and 12-month follow-ups, among the responders, the use of bupropion
or varenicline was low in both arms (8/271 and 11/285, respectively, in the NRT arm, and 4/306 and 9/316,
respectively, in the e-cigarette arm). The reported use of bupropion at 6 months and 12 months was very
low among responders (1/271 and 2/284, respectively, in the NRT arm, none in the e-cigarette arm). The
proportion of responders who reported use of e-cigarettes at 6 and 12 months’ follow-up was considerably
higher in the e-cigarette arm than in the NRT arm [e-cigarette arm: 272/307 (89%) at 6 months and 232/316
(73%) at 12 months; NRT arm: 96/273 (35%) at 6 months and 98/285 (34%) 12 months]. The use of NRT
products in the NRT arm was 48% (131/272) at 6 months and 21% (59/285) at 12 months, higher than in the
e-cigarette arm at both follow-ups [12% (37/306) at 6 months and 9% (29/316) at 12 months].
Among those who provided information, e-liquid was purchased more frequently than e-cigarette devices
during the period from baseline to 6 months and the period from 7 months to 12 months, especially in the
e-cigarette arm. At baseline, although the mean number of purchases of e-cigarette devices was similar
between the arms [0.14 (SD 0.51) in the NRT arm and 0.18 (SD 0.64) in the e-cigarette arm], the mean
number of purchases of e-liquid was much higher in the e-cigarette arm than in the NRT arm [1.01 (SD 17.44)
vs. 0.17 (SD 0.88)]. In the NRT arm, among the 272 of those who provided information at 6 months (on the
period from baseline to 6 months), the mean number of purchases of e-cigarette devices was 0.53 (SD 2.01)
TABLE 22 Mean number of use of smoking cessation help among responders at each follow-up point, by arm
Smoking
cessation help
Trial arm, mean (SD)
NRT E-cigarette
Baseline
(n= 447)
6 months
(n= 270)
12 months
(n= 285)
Baseline
(n= 439)
6 months
(n= 308)
12 months
(n= 314)
GP 0.17 (0.55) 0.10 (0.45) 0.18 (1.01) 0.12 (0.47) 0.04 (0.35) 0.04 (0.36)
NHS SSS 0.16 (0.53) 0.16 (0.74) 0.47 (1.99) 0.18 (1.30) 0.19 (1.62) 0.26 (1.47)
NHS Smoking
Helpline service
0.02 (0.18) 0.01 (0.11) 0.00 (0.06) 0.03 (0.16) 0.00 (0.06) –
TABLE 21 Breakdown of intervention delivery cost (£)
Cost item
Trial arm
NRT (n= 447) E-cigarette (n= 439)
Behavioural support sessions, mean (SD) 77 (15) 80 (12)
NRT/e-cigarette supplies (including LORs), mean (SD) 124 (67) 20 (4)
Pharmacy lists/information sheets 0.05 0.09
Total intervention delivery cost, mean (SD) 201 (77) 100 (13)
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and of e-liquid was 2.12 (SD 6.27), whereas among the 283 of those who provided information at 12 months
(on the period from 7 months to 12 months) it was 0.24 (SD 0.47) for e-cigarette devices and 3.60 (SD 9.44)
for e-liquid. In the e-cigarette arm among the 306 of those who provided information at 6 months (on the
period from baseline to 6 months), the mean number of purchases of e-cigarette devices was 0.75 (SD 1.61)
and of e-liquid was 14.85 (SD 26.68), and among the 315 of those who provided information at 12 months
(on the period from 7 months to 12 months) it was 0.86 (SD 2.10) for e-cigarette devices and 14.30 (SD 24.57)
for e-liquid. The SDs of the purchase of e-liquid were large, especially in the e-cigarette arm, indicating
huge variation in the amount of e-liquid purchased.
Among the responders to the questions, the most-used NRT product was inhalator in both arms at baseline
and 6 months (Figure 9). At 12 months, the inhalator was still the most used product in the e-cigarette
arm, but use of the nicotine spray and patch outnumbered inhalator use in the NRT arm. The use of NRT
products was higher in the NRT arm than in the e-cigarette arm during the 12-month period. In the NRT
arm, a larger proportion of these products were purchased OTC than on prescription, whereas most of
NRT products used in the e-cigarette arm were available on prescription.
As few participants reported using varenicline or bupropion, the mean usage of the two medications for
smoking cessation was close to zero in both arms. The mean number of packs of varenicline in the NRT
arm was 0.12 (SD 0.64) among the 447 participants at baseline, 0.05 (SD 0.34) among the 271 responders
at 6 months and 0.12 (SD 0.67) among the 285 responders at 12 months. In the e-cigarette arm, the
mean number of packs of varenicline was 0.06 (SD 0.47) among the 439 participants at baseline, 0.04
(SD 0.39) among the 306 responders at 6 months and 0.08 (SD 0.52) among the 316 responders at
12 months. The highest mean number of packs of bupropion was reported among 285 responders in the
NRT arm at 12 months, which was 0.01 (SD 0.13).
Combining the unit costs and the usage, the mean costs of smoking cessation help, NRT products,
varenicline and bupropion were calculated. Participants’ expenses on purchasing e-cigarettes, including
refills, were estimated based on self-report spend. These are presented in Table 23, by time and arm.
Large SDs in comparison with the mean values indicated a skewed distribution of costs in either arm.
Health-care services use
Similar to the use of SSSs, wider utilisation of health-care services showed a skewed distribution among
the participants. At baseline, the service with the highest use was hospital outpatient attendance, with one
participant in the NRT arm reporting 96 visits. At 6 months, one participant in the e-cigarette arm reported
having received 90 prescriptions in the previous 6 months, while one participant in the NRT arm reported
60 prescriptions. One participant in each arm reported 50 hospital outpatient attendances in the 6 months
after baseline. At 12 months, one participant in each arm reported having received 50 prescriptions from
6 to 12 months’ follow-up. One participant in the e-cigarette arm reported 49 nights’ inpatient stay,
whereas the highest number of hospital inpatient nights in the NRT arm was 42. From 6 to 12 months’
follow-up, one participant in the NRT arm reported 48 home visits from a practice nurse; this service use
was rarely seen otherwise.
The mean use of most of the health-care services was less than one occasion during a 6-month period, but
the SDs were large (see Appendix 1, Table 38). The most used services were GP visits, followed by hospital
outpatient attendance. In correspondence with the use of services, the responders at each time point
reported at least two prescriptions on average within a 6-month period.
Combining the usage of the services and their unit costs, the mean health-care services costs were £612
(SD £2294) in the NRT arm at baseline (n = 447), £422 (SD £1388) at 6 months (n = 271) and £519
(SD £3036) at 12 months (n = 284). In the e-cigarette arm, the mean health-care services costs were
£512 (SD £1299) at baseline (n = 439), £438 (SD £1489) at 6 months (n = 306) and £575 (SD £2288) at
12 months (n = 317). The large SDs followed the skewed pattern of usage.
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FIGURE 9 Mean reported usage of NRT products on prescription and purchased OTC among responders at each
follow-up point, by arm. (a) Baseline; (b) 6 months; and (c) 12 months.
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Quality of life
The mean EQ-5D-5L scores recorded on the visual analogue scale (VAS) for the NRT arm were 71.1
(SD 17.4) at baseline (n = 447), 73.0 (SD 18.0) at 6 months (n = 272) and 72.1 (SD 18.2) at 12 months
(n = 282). In the e-cigarette arm, the mean VAS score was 70.6 (SD 17.8) at baseline (n = 439), 72.9
(SD 17.3) at 6 months (n = 306) and 74.0 (SD 17.9) at 12 months (n = 315).
At all follow-up points, the majority of the responders reported level 1 (no problem in that dimension)
across all five dimensions (Table 24). Of the five dimensions, the percentage of responders who reported
no problems in mobility, self-care and usual activities remained > 80% at any time point in either arm.
The best perceived dimension by the responders was self-care, followed by usual activities and mobility.
The proportion of no pain or discomfort was similar in both arms: 70% in the NRT arm and 69% in the
e-cigarette arm, at baseline. The proportion who did not feel anxious or depressed was on a similar level
(71% in the NRT arm and 69% in the e-cigarette arm). At 6 months, 79% of the responders in both arms
reported no pain or discomfort, and 75% of the responders in the NRT arm and 79% of the responders in
the e-cigarette arm reported not feeling anxious or depressed. At 12 months, 80% of the responders in
both arms reported no pain or discomfort, and 78% of the responders in the NRT arm and 84% of the
responders in the e-cigarette arm reported not feeling anxious or depressed. The number reporting being
unable to perform tasks, extreme pain/discomfort or anxiety/depression (level 5) did not exceed 10 responders
at each follow-up point in either arm.
Using the mapping technique recommended by NICE and replacing missing values as a result of death
with zero, the mean utility scores in the NRT arm were 0.878 (SD 0.180) at baseline (n = 447), 0.881
(SD 0.217) at 6 months (n = 271) and 0.891 (SD 0.206) at 12 months (n = 281). In the e-cigarette arm,
the mean utility scores were 0.868 (SD 0.190) at baseline (n = 439), 0.886 (SD 0.200) at 6 months
(n = 306) and 0.897 (SD 0.208) at 12 months (n = 315).
TABLE 23 Mean cost of smoking cessation related services/products among responders at each follow-up point, by arm
Trial arm
NRT E-cigarette
Baseline 6 months 12 months Baseline 6 months 12 months
Cost of smoking cessation help
Number of responders 447 271 286 439 308 315
Mean cost (SD) (£) 9 (25) 6 (22) 14 (55) 8 (29) 5 (33) 6 (28)
Cost of NRT products
Number of responders 447 267 283 439 306 316
On prescription, mean cost (SD) (£) 20 (155) 45 (188) 17 (132) 17 (144) 18 (131) 22 (185)
Over the counter, mean cost (SD) (£) 22 (221) 61 (534) 44 (274) 9 (88) 7 (68) 7 (76)
Expenses on e-cigarettes
Number of responders 447 272 282 439 305 312
Mean cost (SD) (£) 3 (12) 20 (46) 26 (64) 4 (27) 77 (95) 80 (117)
Cost of bupropion
Number of responders 447 272 285 439 306 317
Mean cost (SD) (£) 0 (2) 0 (2) 0 (5) 0 (2) – –
Cost of varenicline
Number of responders 447 272 286 439 306 317
Mean cost (SD) (£) 4 (24) 2 (12) 4 (25) 2 (17) 1 (15) 3 (19)
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TABLE 24 The number and percentage of responders for each level of the five dimensions of the EQ-5D-5L at each follow-up point, by arm
Level
EQ-5D-5L dimension, n (%)
Mobility Self-care Usual activities Pain/discomfort Anxiety/depression
NRT E-cigarette NRT E-cigarette NRT E-cigarette NRT E-cigarette NRT E-cigarette
Baseline (NRT arm, n = 447; e-cigarette arm, n = 439)
1 389 (87) 369 (84) 428 (96) 415 (95) 388 (87) 380 (87) 313 (70) 302 (69) 316 (71) 305 (69)
2 23 (5) 33 (8) 10 (2) 12 (3) 30 (7) 32 (7) 68 (15) 72 (16) 74 (17) 82 (19)
3 20 (4) 26 (6) 6 (1) 8 (2) 21 (5) 17 (4) 46 (10) 46 (10) 44 (10) 43 (10)
4 15 (3) 11 (3) 3 (1) 4 (1) 8 (2) 9 (2) 19 (4) 13 (3) 11 (2) 5 (1)
5 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (0) 1 (0) 6 (1) 2 (0) 4 (1)
6 months (NRT arm, n = 270; e-cigarette arm, n = 306)
1 236 (87) 264 (86) 251 (93) 286 (93) 241 (89) 274 (90) 214 (79) 241 (79) 203 (75) 241 (79)
2 15 (6) 13 (4) 10 (4) 6 (2) 9 (3) 9 (3) 16 (6) 22 (7) 32 (12) 29 (9)
3 12 (4) 17 (6) 6 (2) 10 (3) 11 (4) 18 (6) 31 (11) 29 (9) 26 (10) 22 (7)
4 6 (2) 11 (4) 1 (0) 3 (1) 6 (2) 2 (1) 5 (2) 12 (4) 5 (2) 11 (4)
5 1 (0) 1 (0) 2 (1) 1 (0) 3 (1) 3 (1) 4 (1) 2 (1) 4 (1) 3 (1)
12 months (NRT arm, n = 281; e-cigarette arm, n = 314)
1 245 (87) 274 (87) 267 (95) 297 (95) 255 (91) 289 (92) 226 (80) 251 (80) 220 (78) 264 (84)
2 14 (5) 15 (5) 5 (2) 7 (2) 8 (3) 6 (2) 22 (8) 27 (9) 30 (11) 11 (4)
3 7 (2) 10 (3) 4 (1) 3 (1) 6 (2) 7 (2) 21 (7) 22 (7) 25 (9) 31 (10)
4 13 (5) 14 (4) 3 (1) 5 (2) 7 (2) 9 (3) 8 (3) 11 (4) 4 (1) 6 (2)
5 2 (1) 1 (0) 1 (0) 2 (1) 4 (1) 3 (1) 3 (1) 3 (1) 2 (1) 2 (1)
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Primary analysis
Missing data
Taking into account the costs and quality of life at each time point, and other baseline covariates for
adjustment, the level of missing data for individual variables is shown in Table 25. The pattern of missing
data showed that in most cases the reason for missing data was loss to follow-up. Missing data on
individual sections were rare. The level of the missing data was highest (35%) at 6 months and the
number of imputations was set to 35 accordingly.
Incremental cost-effectiveness analysis
The primary analysis was conducted from the NHS and PSS perspectives. Therefore, participants’ spending
on purchasing e-cigarettes and OTC NRT products and prescription charges for redeeming the
pharmacotherapies were not included in the following costs.
Smoking cessation help costs in the 6 months before baseline were £9 [standard error (SE) £1] per
participant in the NRT arm and £8 (SE £1) per participant in the e-cigarette arm. Pharmacotherapy costs
(including NRT on prescription, varenicline and bupropion) in the same period were £24 (SE £7) per
participant in the NRT arm and £20 (SE £7) per participant in the e-cigarette arm. The mean cost of
health-care service use was £612 (SE £108) in the NRT arm and £512 (SE £62) in the e-cigarette arm. In total,
the mean cost to the NHS in the 6 months before baseline was £645 (SE £109) in the NRT arm and £539
(SE £62) in the e-cigarette arm.
The mean cost of smoking cessation help was generally low in both arms, in comparison with other costs
(Table 26). In the 6 months post TQD, the mean pharmacotherapy cost in the NRT arm was twice that in
the e-cigarette arm (£38 vs. £16), whereas the mean cost of health-care service use in the e-cigarette arm
was higher than in the NRT arm (£475 vs. £382). From 6 months to 12 months post TQD, the mean cost
of pharmacotherapies became similar in both arms (£19 in the NRT arm and £21 in the e-cigarette arm).
The mean cost of health-care service use in both arms was higher than in the previous 6-month period,
with the e-cigarette arm costs remaining higher than the NRT arm costs. The mean total cost to the NHS
increased slightly in both arms from 6 months post TQD to 6–12 months post TQD. In the NRT arm, it
increased from £426 (SE £65) per participant in the 6 months post TQD to £490 (SE £124) per participant
in the 6 months before the 12-month follow-up. In the e-cigarette arm, costs increased from £496 (SE £100)
per participant in the 6 months post TQD to £573 (SE £109) per participant in the 6 months before the
12-month follow-up.
In the NRT arm, the mean EQ VAS score increased from 71.1 (SE 0.8) at baseline to 73.7 (SE 1.0) at
6 months, then dropped to 72.6 (SE 1.0) at 12 months. In the e-cigarette arm, the mean EQ VAS increased
from 70.6 (SE 0.9) at baseline to 73.2 (SE 0.9) at 6 months, then to 74.6 (SE 0.9) at 12 months. The mean
EQ-5D-5L utility score in both arms presented an upwards trend. In the NRT arm, the mean utility score
was 0.878 (SE 0.008) at baseline, 0.882 (SE 0.011) at 6 months and 0.887 (SE 0.011) at 12 months. In the
e-cigarette arm, the mean utility score was 0.868 (SE 0.009) at baseline, 0.888 (SE 0.010) at 6 months and
0.898 (SE 0.011) at 12 months.
The mean EQ VAS score in the e-cigarette arm was lower than that in the NRT arm at baseline and
6 months but became higher at 12 months (Figure 10). Although the increase was maintained in the
e-cigarette arm, the mean EQ VAS score in the NRT arm peaked at 6 months and dropped slightly at
12 months. The mean EQ-5D-5L utility score in the e-cigarette arm started lower than that in the NRT arm
but became higher from 6 months onwards. The increase in the e-cigarette arm was slightly more drastic
than in the NRT arm, especially from baseline to 6 months.
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TABLE 25 Number and percentage of missing data on variables in the imputation model
Variable Missing values, n (%)
Age 0 (0)
Sex 0 (0)
Trial site 0 (0)
Entitlement to free prescriptions 0 (0)
Ethnicity 0 (0)
Intervention cost
Training 0 (0)
Delivery 0 (0)
Baseline FTCD 0 (0)
Smoking cessation help cost
Baseline 0 (0)
6 months 307 (35)
12 months 285 (32)
Pharmacotherapies prescription cost
Baseline 0 (0)
6 months 313 (35)
12 months 288 (33)
Expenses on NRT OTC
Baseline 0 (0)
6 months 313 (35)
12 months 287 (33)
Health-care services cost
Baseline 0 (0)
6 months 309 (35)
12 months 285 (32)
Expenses on e-cigarettes
Baseline 0 (0)
6 months 309 (35)
12 months 292 (33)
Prescription charges on pharmacotherapies
Baseline 0 (0)
6 months 185 (21)
12 months 172 (19)
Utility score
Baseline 0 (0)
6 months 309 (35)
12 months 290 (33)
VAS
Baseline 0 (0)
6 months 308 (35)
12 months 289 (33)
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The mean intervention cost per participant was £201 (SE £4) in the NRT arm and £105 (SE £1) in the e-cigarette
arm. The difference was mainly as a result of the provision of NRT products in the NRT arm. Smoking cessation
costs outside the intervention were £77 (SE £13) per participant in the NRT arm and £48 (SE £11) in the
e-cigarette arm, during the 12 months post TQD. The mean cost of health-care service use was higher in the
e-cigarette arm [£1022 (SE £147)] than in the NRT arm [£839 (SE £162)]. In total, the mean cost to the NHS
was similar between arms: £1116 (SE £163) in the NRT arm and £1174 (SE £147) in the e-cigarette arm. The
unadjusted difference in costs was £58 (95% CI –£339 to £410) per participant, with the e-cigarette arm
having higher costs. After adjusting for age, sex, FTCD score at baseline, trial centre, entitlement to free
prescription and the costs to the NHS at baseline, the mean cost per participant in the e-cigarette arm was
£11 (95% CI –£104 to £147) higher than in the NRT arm (Table 27).
TABLE 26 Breakdown of mean costs to the NHS in the 6 months before baseline, after TQD and before 12 months,
by arm
Resource
Trial arm, mean (SE) (£)
NRT (n= 447) E-cigarette (n= 439)
Mean cost in the 6 months before baseline
Smoking cessation help cost 9 (1) 8 (1)
Pharmacotherapy cost 24 (7) 20 (7)
Health-care service use cost 612 (108) 512 (62)
Cost to the NHS 645 (109) 539 (62)
Mean cost in the 6 months post TQD
Smoking cessation help cost 6 (1) 4 (2)
Pharmacotherapy cost 38 (8) 16 (6)
Health-care service use cost 382 (63) 475 (100)
Cost to the NHS 426 (65) 496 (100)
Mean cost from 6 months to 12 months post TQD
Smoking cessation help cost 14 (3) 6 (2)
Pharmacotherapy cost 19 (5) 21 (8)
Health-care service use cost 457 (124) 546 (109)
Cost to the NHS 490 (124) 573 (109)
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FIGURE 10 Mean EQ VAS score and EQ-5D-5L utility score at baseline, 6 months and 12 months, by arm.
DOI: 10.3310/hta23430 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 43
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hajek et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
The mean QALY gain was 0.882 (SE 0.009) per participant in the NRT arm and 0.886 (SE 0.008) per
participant in the e-cigarette arm. The unadjusted difference in mean QALYs was 0.003 (95% CI –0.017 to
0.025), with the e-cigarette arm having a greater QALY gain. After adjusting for age, sex, FTCD score at
baseline, trial centre, entitlement to free prescription and utility score at baseline, the mean QALY gain per
participant was 0.010 (95% CI –0.003 to 0.023) higher in the e-cigarette arm than in the NRT arm.
Dividing the adjusted difference in mean total costs by the adjusted difference in mean QALYs gained, the
ICER was, therefore, £1100 per QALY gained, comparing the e-cigarette arm with the NRT arm. This was
considered cost-effective, comparing it against the WTP threshold of £20,000 per QALY.
The bootstrapped 95% CI for the ICER was wide, ranging from –£36,947 to £47,414 per QALY gained.
The CEP gave a clearer illustration of the uncertainty surrounding the £1100 point estimate (see Figure 11a).
It shows that the majority of the bootstrapped ICERs fall under the line marking the £20,000 per QALY
threshold indicating that an intervention is likely to be cost-effective. The CEAC presents the probability of
e-cigarettes being cost-effective, in comparison with NRT, at different WTP levels (see Figure 11b). The
probability reaches 50% at a very low WTP level. By £20,000 per QALY, the probability of an e-cigarette
intervention being cost-effective was ≈87%; at £30,000 per QALY, it was 90%. This indicates an
intervention that is highly likely to be cost-effective from the NHS and PSS perspectives.
Complete-case analysis
Taking into account of all the variables required, the CCA was conducted based on 458 participants (254 in
the e-cigarette arm and 204 in the NRT arm). Among complete cases, the mean cost of smoking cessation
help in the 6 months before baseline, in the 6 months post TQD and from 6 to 12 months post TQD was
relatively low in both arms: £7 (SD £17), £7 (SD £24) and £14 (SD £45), respectively, in the NRT arm and
£8 (SD £24), £4 (£29) and £6 (SD £29), respectively, in the e-cigarette arm. The mean pharmacotherapy cost
among complete cases in the NRT arm was £15 (SD £67) in the 6 months before baseline; it peaked at
£37 (SD £129) in the 6 months post TQD and dropped back to the baseline level from 6 to 12 months post
TQD [£14 (SD £54)]. In the e-cigarette arm, the mean pharmacotherapy cost among complete cases reduced
TABLE 27 Incremental cost-effectiveness analysis comparing the e-cigarette arm with the NRT arm
Costs, QALYs and ICER
Trial arm
NRT (n= 447) E-cigarette (n= 439)
Costs during the trial period (£)
Intervention cost (SE) 201 (4) 105 (1)
Smoking cessation costs (SE) 77 (13) 48 (11)
Health-care costs (SE) 839 (162) 1022 (147)
Total costs during the trial period (SE) 1116 (163) 1174 (147)
Difference in total costs during the trial period (95% CI)
Unadjusted 58 (–339 to 410)
Adjusted 11 (–104 to 147)
Quality of life during the trial period
QALYs (SE) 0.882 (0.009) 0.886 (0.008)
Difference in QALYs (95% CI)
Unadjusted 0.003 (–0.017 to 0.025)
Adjusted 0.010 (–0.003 to 0.023)
ICER (£)
ICER at 12 months post TQD (95% CI) 1100 per QALY gained (–36,947 to 47,414)
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from £24 (SD £179) in the 6 months before baseline to £17 (SD £119) in the 6 months post TQD, and
remained on the same level from 6 to 12 months post TQD [£19 (SD £125)]. In the NRT arm, the mean
health-care service use cost was highest in the 6 months before baseline [£666 (SD £2810)]. It decreased to
£462 (SD £1552) in the 6 months post TQD and increased again to £590 (SD £3561) from 6 to 12 months
post TQD. In the e-cigarette arm, the mean health-care service use cost went in the opposite direction.
It started from £561 (SD £1478) in the 6 months before baseline, reduced to £457 (SD £1565) in the
6 months post TQD and reached the highest value, £653 (SD £2540), from 6 to 12 months post TQD.
In total, the mean costs to the NHS were £688 (SD £2811), £506 (SD £1578) and £617 (SD £3560) in the
NRT arm, in the three 6-month periods. In the e-cigarette arm, they were £593 (SD £1490), £478 (£1574)
and £678 (£2548), for the same periods. Compared with the primary analysis, except for the e-cigarette arm
in the 6 months post TQD, the mean costs to the NHS were all higher among complete cases than in the
imputed data set (Figure 12). The biggest differences were in the mean costs from 6 to 12 months post
TQD in both arms [£496 (primary analysis) vs. £617 (CCA) in the NRT arm and £573 (primary analysis) vs.
£678 (CCA) in the e-cigarette arm]. In both arms, the relative position of the mean costs in the first and
last 6-month periods remained the same as in the primary analysis (i.e. the last 6-month period was more
costly than the first 6-month period). However, the relative position between arms was reversed in the
first 6-month period, with costs higher in the NRT arm than in the e-cigarette arm among complete cases
(in contrast to the primary analysis, in which costs in the same period were higher in the e-cigarette arm).
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FIGURE 11 (a) Cost-effectiveness plane and (b) CEAC, comparing the e-cigarette arm with the NRT arm.
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The mean VAS score among the complete cases in the NRT arm (n = 204) was 70.9 (SD 16.6) at baseline,
73.2 (SD 17.0) at 6 months and 72.2 (SD 18.0) at 12 months. In the e-cigarette arm (n = 254), it was 69.9
(SD 17.7) at baseline, 72.7 (SD 17.2) at 6 months and 74.3 (SD 16.9) at 12 months among the complete
cases. Compared with the primary analysis, the mean VAS score was lower in the complete cases at all
time points and in both arms (Figure 13). The difference in the NRT arm was less pronounced than that in
the e-cigarette arm. However, the general pattern of change remained the same: in the NRT arm VAS
score rose from baseline to 6 months and dropped slightly at 12 months, whereas in the e-cigarette arm it
increased from baseline to 6 months and from 6 to 12 months.
The proportion of the participants in the NRT arm selecting each level of the five dimensions of the EQ-5D-5L
was shown in Figure 14. Overall, most participants (> 80%) among the complete cases had no problems in
the areas of mobility, self-care and usual activities, with the best scores being in self-care, at any time point
(Figures 14 and 15). The proportion of participants reporting no pain/discomfort and not anxious/depressed
was relatively lower but increased from ≈70% at baseline to ≈80% at 12 months in both arms. Few
participants felt that they were unable to perform usual tasks, felt extreme pain/discomfort or felt extremely
anxious/depressed.
Among the complete cases in the NRT arm, the mean utility score was 0.885 (SD 0.162) at baseline, 0.897
(SD 0.198) at 6 months and 0.893 (SD 0.205) at 12 months. In the e-cigarette arm, the mean utility score
was 0.868 (SD 0.193) at baseline, 0.882 (SD 0.199) at 6 months and 0.900 (SD 0.202) at 12 months.
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
M
e
a
n
 s
co
re
Baseline 6 months 12 months Baseline 6 months
NRT E-cigarette
Trial arm
12 months
Imputed (NRT = 447, 
E-cigarette = 439)
Complete (NRT = 204, 
E-cigarette = 254)
71.1 70.9 73.7 73.2 72.6 72.2 70.6 69.9
73.2 72.7 74.6 74.3
FIGURE 13 Comparison of mean VAS score between the primary analysis and CCA.
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In comparison with the primary analysis, the mean utility score among complete cases was higher in the
NRT arm at all three time points (Figure 16). Instead of a gradual upwards trend in the primary analysis,
the CCA showed a sharp increase from baseline to 6 months and then dropped slightly at 12 months.
In the e-cigarette arm, the mean utility score was the same as in the primary analysis at baseline, became
lower at 6 months, and reached a slightly higher level at 12 months. The upwards trend remained but
became gentler from baseline to 6 months.
These shifts resulted in a change in relative position at 6 months. Although the mean utility score was
still higher in the NRT arm than in the e-cigarette arm at baseline and lower in the NRT arm than in the
e-cigarette arm at 12 months, it was much higher in the NRT arm at 6 months than in the e-cigarette arm.
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FIGURE 15 Proportion of EQ-5D-5L dimensions among complete cases in the e-cigarette arm.
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This led to an increase in the area under the curve of three data points in the NRT arm and a reduction in
the area under the curve in the e-cigarette arm. Therefore, the mean QALY gain was higher than in the
primary analysis in the NRT arm (0.893 vs. 0.882) and lower than in the primary analysis in the e-cigarette
arm (0.883 vs. 0.886).
The total cost to the NHS during the trial period was £1339 (SD £4616) per participant in the NRT arm,
which was higher than that in the e-cigarette arm [£1264 (SD £3031)] (Table 28). After adjusting for age,
sex, FTCD score at baseline, trial centre, entitlement to free prescriptions and the costs to the NHS at
baseline, the adjusted difference in total costs between arms during the trial period was –£96 (95% CI
–£304 to £81) in complete cases, with the e-cigarette arm having lower costs than the NRT arm. The
negative cost difference indicated a less costly intervention, compared with the control, at a point estimation.
TABLE 28 Incremental cost-effectiveness analysis comparing the e-cigarette arm with the NRT arm in the CCA
Costs, QALYs and ICER
Trial arm
NRT (n= 204) E-cigarette (n= 254)
Costs during the trial period (£)
Intervention cost (SD) 216 (73) 108 (10)
Smoking cessation costs (SD) 71 (165) 46 (190)
Health-care costs (SD) 1051 (4611) 1110 (3018)
Total costs during the trial period (SD) 1339 (4616) 1264 (3031)
Difference in total costs during the trial period (95% CI)
Unadjusted –75 (–868 to 587)
Adjusted –96 (–304 to 81)
Quality of life during the trial period
QALYs (SD) 0.893 (0.162) 0.883 (0.170)
Difference in QALYs (95% CI)
Unadjusted –0.010 (–0.041 to 0.021)
Adjusted 0.003 (–0.018 to 0.023)
ICER (£)
ICER at 12 months post TQD (95% CI) E-cigarette dominant (less costly, more effective) (–194,201 to 171,348)
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
1.000
0.900
0.800
M
e
a
n
 u
ti
li
ty
 s
co
re
Baseline 6 months 12 months Baseline 6 months
NRT E-cigarette
Trial arm
12 months
Imputed (NRT = 447, 
E-cigarette = 439)
Complete (NRT = 204, 
E-cigarette = 254)
0.878 0.885 0.882 0.897 0.887 0.893 0.868 0.868 0.888 0.882 0.898
0.900
FIGURE 16 Comparison of mean utility scores between the primary analysis and CCA.
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After adjusting for age, sex, FTCD score at baseline, trial centre, entitlement to free prescriptions and utility
score at baseline, the adjusted difference in QALYs was 0.003 (95% CI –0.018 to 0.023) in complete
cases, which was smaller than in the primary analysis. Combining the difference in costs and in QALY
(i.e. looking at the difference in costs and in QALY together), the e-cigarette arm was less costly but more
effective than the NRT arm, among complete cases, which made the e-cigarette arm dominant and cost-
effective. The bootstrapped replicates produced a wide 95% CI for ICER with the upper bound still lower
than £20,000.
The CEP illustrated the 5000 bootstrapped replicates of matching adjusted difference in costs and in
QALYs (Figure 17a). The majority of the dots fell under the zero cost difference line, supporting the point
estimation of the e-cigarette arm being less costly. The distribution of QALY difference was more balanced
between the two sides of the zero QALY difference line, concentrating slightly more on the positive side.
The majority of the replicated ICERs fell under the £20,000 per QALY line, indicating a high probability
that e-cigarettes are cost-effective. Converting that onto a CEAC, e-cigarettes showed a 75% probability
of being cost-effective compared with NRT (Figure 17b). The curve started from close to 90% at the null
WTP threshold, and declined gradually to 70% at the £30,000 WTP thresholds. This was because the more
monetary value being put on 1 QALY, the less likely an intervention resulting in a negative QALY gain
would be considered cost-effective, even if it is less costly.
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FIGURE 17 (a) Cost-effectiveness plane and (b) CEAC comparing the e-cigarette arm with the NRT arm, in the CCA.
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Although the CCA produced a negative point estimate of cost difference, it also gave a less significant
improvement in QALYs than did the primary analysis. This suggests that the multiple imputation had the
effect of reducing the difference in costs but enlarging the difference in QALYs, though not by much.
However, the conclusion did not change.
Secondary analysis
Comparison of weekly nicotine replacement therapy dispensed and nicotine replacement
therapy used
Information on NRT use in the first week, both self-reported and from dispensing records, was available for
385 of the 447 participants in the NRT arm. The corresponding numbers at later time points were 346 at
2 weeks post TQD, 321 at 3 weeks post TQD and 335 at 4 weeks post TQD. Figure 18 presents the numbers
of each NRT item on record during the same weeks. The numbers do not sum to the number of participants
because of the dual use of NRT products.
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FIGURE 18 Comparison of recorded dispense of NRT and self-reported use of NRT in the same week from 1 week
to 4 weeks post TQD in the NRT arm. (a) One week post TQD (n= 385); (b) 2 weeks post TQD (n= 346); (c) 3 weeks
post TQD (n = 321); and (d) 4 weeks post TQD (n= 335). (continued )
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At 1 week post TQD, the self-reported numbers of NRT products were not much different from the
numbers recorded as dispensed. The most popular products in both cases were 24-hour patch (21 mg),
followed by inhalator, 16-hour patch (25 mg) and mouth spray. At 2 weeks post TQD, the most popular
products were still the four products mentioned above, but the self-reported numbers of products used
exceeded the numbers recorded as dispensed. Self-reported use of inhalator was similar to self-reported
use of 24-hour patch (21 mg) but was twice the number of recorded dispenses of inhalator. The self-
reported use of mouth spray was almost three times the number on recorded dispense. These patterns
continued, to slightly different degrees, in the third and fourth weeks post TQD.
The mean NRT cost according to the dispensing records on TQD was £50 (SD £12), which is slightly higher
than the mean NRT cost according to self-report at 1 week post TQD [£45 (SD £16); n = 385]. The mean
NRT cost according to the dispensing record at 1 week post TQD was £23 (SD £23), which is lower than
the mean NRT cost according to self-report at 2 weeks post TQD [£43 (SD £18); n = 346]. Similarly, the
mean NRT cost according to the dispensing record at 2 weeks post TQD was £23 (SD £22), which is lower
than the mean NRT cost according to self-report at 3 weeks post TQD [£42 (SD £19); n = 321]. The mean
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FIGURE 18 Comparison of recorded dispense of NRT and self-reported use of NRT in the same week from 1 week
to 4 weeks post TQD in the NRT arm. (a) One week post TQD (n= 385); (b) 2 weeks post TQD (n= 346); (c) 3 weeks
post TQD (n= 321); and (d) 4 weeks post TQD (n= 335).
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NRT cost according to the dispensing record at 3 weeks post TQD was £21 (SD £23), which is lower than
the mean NRT cost according to self-report at 4 weeks post TQD [£38 (SD £20]); n = 335]. Except for the
first week post TQD, the mean self-reported NRT cost was generally higher than the cost of recorded
dispense.
A complete record of NRT use, from dispensing on TQD to self-report at 4 weeks post TQD, was available
for a total of 266 participants in the NRT arm. The mean cost of NRT according to dispense data was £124
(SD £53), whereas the mean cost of NRT according to self-reported use was £175 (SD £54).
Further exploring the weekly NRT dispense and use, 248 participants were provided with two products in
the first week post TQD and used both, and 31 were provided with one product and used it. A total of
82 participants used either one of the two provided products or another product in addition to the one
provided product. A total of 10 participants used only products not provided whether or not they already
received products provided as part of the trial. A further 14 participants used no NRT products, provided or
not (Figure 19).
In the following weeks, more participants reported using NRT products that were different from their provided
products and fewer participants reported using two provided products. These were the causes of discrepancy
between two estimated mean NRT costs. Assuming that all products were prescribed or provided by NHS SSSs,
the mean intervention cost in the NRT arm would increase by ≈£50 per participant.
Costs of smoking cessation aids to the NHS and participants’ expenses on smoking
cessation
The cost to the NHS of pharmacotherapies has been reported in the primary analysis. The following
analyses were performed on the same data set as in the primary analysis, that is on the data set
comprising 447 participants in the NRT arm and 439 participants in the e-cigarette arm, and missing data
were imputed.
Figure 20 showed a comparison of participants’ expenses on smoking cessation aids (pharmacotherapies
and e-cigarettes). Pharmacotherapies include various NRT products, bupropion and varenicline. The last
two are available only on prescription. Taking into account those who were exempted from prescription
charges, the mean cost of prescription products was low in both arms. In the NRT arm, it was £2 (SE £1) in
the 6 months before baseline, £18 (SE £2) in the 6 months post TQD and £2 (SE £1) from 6 to 12 months
post TQD. In the e-cigarette arm, it was £1 (SE £0) in the 6 months before baseline, £0 (SE £0) in the
6 months post TQD and £3 (SE £2) from 6 to 12 months post TQD.
The amount spent on OTC NRT products was much higher in the NRT arm than in the e-cigarette arm in
all three 6-month periods: £22 (SE £10) versus £9 (SE £4) in the 6 months before baseline, £47 (SE £21)
versus £6 (SE £3) in the 6 months post TQD and £42 (SE £15) versus £6 (SE £3) from 6 to 12 months post
TQD (see Figure 20).
In contrast, the purchase of e-cigarettes was considerably more common in the e-cigarette arm than in the
NRT arm. The mean amount spent on e-cigarettes was similar in both arms in the 6 months before baseline
[NRT arm, £3 (SE £1); e-cigarette arm, £4 (SE £1)]. However, the mean amount spent on e-cigarettes in the
e-cigarette arm was £73 (SE £5) in the 6 months post TQD and £80 (SE £6) from 6 to 12 months post TQD,
whereas participants in the NRT arm spent, on average, £21 (SE £3) on e-cigarettes in the 6 months post TQD
and £28 (SE £4) from 6 to 12 months post TQD.
As defined in the primary analysis, SSS costs to the NHS covered smoking cessation help (advice from a GP,
Specialist Smoking Cessation Service and Smoking Cessation Helpline) and pharmacotherapies (NRT,
bupropion and varenicline) but excluded intervention costs. Participants’ expenses on smoking cessation
comprised prescription charges, when applicable, NRT purchased OTC and purchase of e-cigarettes.
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In the 6 months before baseline, SSS costs to the NHS were £33 (SE £8) per participant in the NRT arm
and £27 (SE £7) per participant in the e-cigarette arm. Participants’ expenses on smoking cessation
amounted to £27 (SE £11) per participant in the NRT arm and £14 (SE £4) per participant in the e-cigarette
arm (Table 29).
In the 6 months post TQD, the cost to the NHS of SSSs was £44 (SE £8) per participant in the NRT arm,
higher than in the e-cigarette arm [£20 (SE £6)]. Participants’ expenses on smoking cessation averaged £86
(SE £21) per participant in the NRT arm and £80 (SE £6) per participant in the e-cigarette arm.
From 6 to 12 months post TQD, the cost to the NHS of SSSs was £33 (SE £8) per participant in the NRT
arm and £27 (SE £9) per participant in the e-cigarette arm. Participants’ expenses on smoking cessation
averaged £72 (SE £15) per participant in the NRT arm and £89 (SE £7) per participant in the e-cigarette arm.
In the 12 months post TQD, excluding intervention costs, the mean cost to the NHS of SSSs was £77 (SE £13)
per participant in the NRT arm and £48 (SE £11) per participant in the e-cigarette arm. The mean cost of
smoking cessation to participants was £158 (SE £27) per participant in the NRT arm and £169 (SE £11) per
participant in the e-cigarette arm.
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FIGURE 20 Participants’ expenses on smoking cessation aids in the 6 months before baseline, after TQD and before
the 12-month follow-up, by arm.
TABLE 29 Smoking cessation costs and participants’ expenses on smoking cessation in the 6 months before
baseline, after TQD and before the 12-month follow-up, by arm
Time point and costs
Trial arm, mean (SE) (£)
NRT (n= 447) E-cigarette (n= 439)
6 months before baseline
SSS costs to the NHS 33 (8) 27 (7)
Participants’ expenses on smoking cessation 27 (11) 14 (4)
6 months post TQD
SSS costs to the NHS 44 (8) 20 (6)
Participants’ expenses on smoking cessation 86 (21) 80 (6)
6 to 12 months post TQD
SSS costs to the NHS 33 (8) 27 (9)
Participants’ expenses on smoking cessation 72 (15) 89 (7)
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Although participants’ expenses did not appear to be different between arms, the mean cost to the NHS
of SSSs was slightly lower in e-cigarette arm than in the NRT arm. Taking into account the intervention
costs, the mean smoking cessation cost to the NHS was £278 (SE £14) per participant in the NRT arm and
£152 (SE £11) per participant in the e-cigarette arm.
Long-term cost and outcome projection
Parameters estimated from the trial
The abstinence rate at 12 months was 9.9% in the NRT arm and 18.0% in the e-cigarette arm. The
intervention costs in both groups are reported in the preceding section. The wider health-care costs and
the QALYs gained over the first 12 months were recalculated from the trial results according to a
participant’s abstinence status at 12 months. Table 30 presents the model parameters estimated from the
trial data. Combining Appendix 1, Table 36, and Table 30, all the model parameters are summarised.
Cost-effectiveness analysis
The mean lifetime smoking-related health-care costs (including costs occurred during trial period) were
estimated at £3175 (SE £161) per participant who used NRT and £3184 (SE £169) per participant who received
e-cigarette. The average QALY gain was estimated at 24.14 (SE 0.31) per person for those in the NRT arm
and 24.28 (SE 0.31) per person for those in the e-cigarette arm. The ICER for the base-case cost-effectiveness
analysis was £65 (95% CI –£12,537 to £13,423) per QALY gained, with the use of e-cigarette more costly
and more effective (see Table 30). This was much lower than the £20,000 per QALY WTP threshold.
TABLE 30 Model parameters estimated from the trial data
Parameter Value (SE) Distribution
Probability of quit at 12 months (%)
NRT arm 9.9 (1.4) Beta
E-cigarette arm 18.0 (1.7) Beta
Intervention cost (£)
NRT arm 201 (4) Gamma
E-cigarette arm 105 (1) Gamma
12-month health-care costs (£)
NRT arm
Those who quit 603 (211) Gamma
Continuing smokers 950 (180) Gamma
E-cigarette arm
Those who quit 1164 (329) Gamma
Continuing smokers 1049 (165) Gamma
QALY gain at 12 months
NRT arm
Those who quit 0.888 (0.028) Gamma
Continuing smokers 0.882 (0.009) Gamma
E-cigarette arm
Those who quit 0.887 (0.019) Gamma
Continuing smokers 0.885 (0.009) Gamma
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Probabilistic sensitivity analyses
The probabilistic sensitivity analysis incorporated the uncertainty in the parameter estimates to provide estimates
of the probability that each intervention would be cost-effective at different WTP thresholds for QALY gains.
Figure 21 illustrates the uncertainty surrounding the ICER estimate at £65 per QALY. Only a small proportion
of the dots fell on the left side of the y-axis, indicating that e-cigarettes are highly likely to be more effective,
in terms of QALYs gained, than NRT. As for the costs, the dots are scattered almost equally on either side
of the x-axis, indicating a similar level of lifetime smoking-related costs between the two arms. The majority
of the dots fell under the £20,000 per QALY line, suggesting a robust conclusion.
The CEAC in Figure 22 shows that e-cigarettes have a higher probability of being cost-effective than NRT
at a very low WTP threshold (£65 per QALY). Beyond that, the probability of e-cigarettes being more
cost-effective rises sharply, reaching 80% at a WTP threshold of £3000 per QALY. Using the £20,000 to
£30,000 per QALY gained WTP thresholds, the CEAC indicates that the probability of e-cigarette being
more cost-effective is between 84.6% and 84.8%, in comparison with NRT.
Conclusion
The intervention costs were £201 (SE £4) per participant in the NRT arm and £105 (SE £1) per participant
in the e-cigarette arm. In the primary analysis, the total costs to the NHS during the 12-month period were
£1116 (SE £163) per participant in the NRT arm and £1174 (SE £146) per participant in the e-cigarette
arm. The adjusted difference in mean total costs was £11 (95% CI –£104 to £147), with the e-cigarette
arm costs being higher. The mean QALY gain per participant was 0.882 (SE 0.009) in the NRT arm and
0.886 (SE 0.008) in the e-cigarette arm. The adjusted difference in mean QALYs was 0.010 (95% CI
–0.003 to 0.023). The ICER was estimated at £1100 per QALY gained (95% CI –£36,947 to £47,414).
TABLE 31 Base-case deterministic cost-effectiveness analysis
Intervention
Lifetime smoking-related
health-care costs, mean (SE) (£) QALY gain, mean (SE)
NRT 3175 (161) 24.14 (0.31)
E-cigarette 3184 (169) 24.28 (0.31)
ICER (incremental cost per additional QALY),
mean (95% CI) (£)
65 (–12,537 to 13,423)
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The CEP and the CEAC showed an 87% probability of cost-effectiveness at a WTP threshold of £20,000 and
a 90% probability of cost-effectiveness at a WTP threshold of £30,000, comparing e-cigarettes with NRT.
These suggest that e-cigarettes are a cost-effective intervention with relatively low uncertainty.
The CCA reported a higher level of uncertainty surrounding the differences in mean total costs and mean
QALYs. It indicated a possible cost-saving intervention with no difference in effectiveness. The conclusion
of e-cigarettes being more cost-effective than NRT was therefore still upheld.
Further exploration of participants’ expenditure on smoking cessation outside the intervention found no
evidence of cost shift from the NHS to the smokers. On the contrary, although participants’ expenses were
similar in each arm, the NHS smoking cessation costs were slightly lower in the e-cigarette arm than in the
NRT arm.
The weekly comparison of NRT dispensed and self-reported NRT in the NRT arm suggested an issue in
compliance with NRT prescription. Although participants still used some form of NRT products, the NRT
products provided by the trial were not always used. If the extra NRT products were obtained through the
NHS, the intervention costs of the NRT arm might be underestimated.
The long-term modelling projected a lifetime ICER of £65 per QALY gained (95% CI –£12,537 to £13,423),
indicating that e-cigarettes would be a highly cost-effective intervention, compared with NRT. The probability
sensitivity analyses proved the conclusion to be robust.
Discussion
The trial collected a large amount of information in a large sample. The total sample size of 886 reduced
the possibility of some participants with particularly high health-care services use being randomised to one
arm and causing imbalance in the total costs. A wide range of smoking cessation related services/products
information and primary and secondary care use information was also collected.
The primary analysis concluded that using e-cigarettes within the UK SSSs is cost-effective compared with
pharmacotherapies. A sensitivity analysis and the long-term modelling that was performed and reported after
the within-trial analyses (including sensitivity analysis) supported this conclusion. There was no evidence to
suggest a difference in costs to the NHS within the 12-month period, although the intervention costs were
lower with e-cigarettes. There was an indication that QALY gain was higher in the e-cigarette arm than in the
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NRT arm during the 12-month period; however, the difference was not significant. The CCA indicated that
using e-cigarettes might be cost-saving while having no effect on QALYs in the 12-month period because,
among the complete cases, health-care service costs and QALYs, although increased in both arms, were
increased to a much greater extent in the NRT arm.
Both EQ VAS and utility scores showed a slight upwards trend in the e-cigarette arm. In the NRT arm,
the EQ VAS score increased at 6 months and dropped marginally at 12 months, whereas the utility score
showed a more gentle increase than in the e-cigarette arm. Among the five dimensions of EQ-5D-5L, most
participants did not report any problems in mobility, self-care or usual activities, which was expected in this
population. The proportions of participants reporting problems were highest for the dimensions of pain/
discomfort and anxiety/depression. Both dimensions appeared to improve through the trial period, with the
greatest improvement occurring in anxiety/depression dimension score in the e-cigarette arm.
It appeared that participants, once introduced to one type of smoking cessation aid, were more likely to
continue using the same aid after the intervention period. Participants in the NRT arm reported more NRT
use than participants in the e-cigarette arm, whereas the participants in the e-cigarette arm reported more
purchase of e-cigarettes than those in the NRT arm. Although some participants switched products or used
a mixture of products, they accounted for only a small fraction of the total.
Originally, the research team were concerned that the introduction of e-cigarettes might shift the cost
of smoking cessation onto individuals trying to quit, because e-cigarettes are not currently provided by
the NHS. However, the results from this analysis showed that participants trying to quit smoking were
likely to purchase some form of cessation aid, whether NRT or e-cigarettes. Therefore, there was no
evidence to suggest that participants who used e-cigarettes spent more money on smoking cessation aids.
As various brands and packages of NRT products are available on the market, we estimated personal
expenditure on NRT products based on prescription costs rather than market prices. Participants’ actual
expenditure on NRT products could be higher than we estimated. For instance, the net ingredient cost of
seven 21 mg/24-hour nicotine patches is £9.87,47 whereas a pack of seven 21 mg/24-hour nicotine patches
costs £8.00 to £30.89 on Amazon UK (Amazon.com, Inc., Bellevue, WA, USA) and £11 to £13 on the
websites of Boots (Nottingham, UK), Superdrug (London, UK) and LloydsPharmacy (Coventry), without
sale discount. Promotional sales and online purchase could reduce the cost to participants but, in general,
the price would be higher than the net ingredient cost.
The reasons for a large proportion of participants not using some or all of the NRTs dispensed were
unclear. It was possible that between the time of dispense and use, the participants looked into NRT
products and decided to use other forms of NRT. The use of a LOR rather than direct product at one of the
sites dispensing could also have led participants at that site to change the product used, as a LOR must be
redeemed in pharmacies, thereby incurring an extra trip and prescription charge if not exempted. It could
also be that, once participants were introduced to the NRT products, they were more likely to be tempted
to try other forms of NRT.
The economic evaluation comparing e-cigarettes with NRT products was conducted on the premise that
the initial products were provided free of charge to the participants, with some guidance. However, this is
not currently the case. To implement this intervention in practice, a systematic shift within various relevant
services might be required, the costs of which were not taken into account in this analysis. Furthermore,
the price of e-cigarettes is changing rapidly, as reflected in this trial. The One Kit originally used in the trial
cost £19.35 per kit, but during the trial period this old version was discontinued and a more expensive
version (£30.54 per kit) had to be used as replacement. In contrast to the relatively stable price of NRT
products, this makes the cost of the intervention uncertain and likely to increase in the future. With the
price rising, participants’ expenditure on e-cigarettes as a smoking cessation aid would also increase.
This results in the conclusion regarding SSS costs to the NHS and a cost shift from the NHS to smokers
becoming less robust.
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Short-term costs and QALYs are not sufficient to reflect the full benefits of smoking cessation. This
long-term model showed a result favourable to the use of e-cigarettes mainly because of the higher
abstinence rate at 12 months in the e-cigarette arm than in the NRT arm. The model did not take into
account the repeated attempt of smoking cessation, in which, in reality, people who failed the first time
might try a second or even third time at a later stage. In addition, although the smoking-related diseases
have been identified and their costs were estimated, the EQ-5D-5L is not a clinical measurement widely
used for these clinical conditions, especially in the acute onset of a condition. The QALYs in the model
were derived based on smoking status and were not disease specific; therefore, it is possible that the
QALY gain from smoking cessation was underestimated.
DOI: 10.3310/hta23430 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 43
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hajek et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
65
Acknowledgements
We would like to thank:
All trial participants and the participating SSSs [Leicester, East Sussex (Quit 51), Tower Hamlets and City of
London] that helped to recruit participants and deliver the trial interventions.
Our TSC and DMEC members, in particular the chairpersons, Professor Ian Roberts and Professor Tim Peto,
lay members, Benjamin Roberts and Brian Eastwood, and Professor Sarah Lewis, for her independent
review of the statistical analysis plan.
Our NIHR research project managers: Simon Bevan, Alexa Cross, Avril Lloyd and Jennifer Cook.
All of the team, current and former, at the Health and Lifestyle Research Unit, QMUL, who assisted with
intervention delivery, data collection and data entry.
The Barts CTU, in particular Dr Irene Kaimi (Senior Statistician), Benoit Aigret, Richard Ostler, Samanah Haidary
and Alberto Stella, for their support throughout the trial.
Contributions of authors
Professor Peter Hajek (Professor of Clinical Psychology) was the Chief Investigator. He co-wrote the
original grant application, co-designed the trial, co-wrote the statistical analysis plan, trained staff,
interpreted the trial findings and led the drafting of the report.
Mrs Anna Phillips-Waller (Research Manager) co-designed the trial, managed the trial, co-wrote the
statistical analysis plan, trained staff, delivered the interventions, contributed to data collection, interpreted
the trial findings and assisted with the drafting of the report.
Dr Dunja Przulj (Postdoctoral Research Assistant) assisted with the management of the trial, trained staff,
delivered the interventions, contributed to data collection, co-wrote the statistical analysis plan, interpreted
the trial findings and assisted with the drafting of the report.
Dr Francesca Pesola (Study Statistician) co-wrote the statistical analysis plan and analysed the final trial
data.
Dr Katie Myers Smith (Research Fellow) was a co-applicant on the grant proposal, trained staff, delivered
the interventions, contributed to data collection, interpreted the trial findings and assisted with the
drafting of the report.
Ms Natalie Bisal (Research Health Psychologist) delivered the interventions, contributed to data collection
and assisted with the drafting of the report.
Ms Jinshuo Li (Research Fellow) co-wrote the statistical analysis plan for health economics analysis,
analysed the health economics trial data, interpreted the results and assisted with the report write-up.
Mr Steve Parrott (Reader in Health Economics) co-wrote the statistical analysis plan for health economics
analysis, analysed the health economics study data, interpreted the results and assisted with the report
write-up.
DOI: 10.3310/hta23430 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 43
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hajek et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
67
Professor Peter Sasieni (Professor of Biostatistics and Cancer Epidemiology) co-wrote the statistical
analysis plan.
Dr Lynne Dawkins (Associate Professor) assisted with recruitment and was involved in the interpretation
of the trial data and write-up of the trial report.
Ms Louise Ross (Stop Smoking Service Manager) advised on trial feasibility, trained staff, supported
intervention delivery, contributed to data collection and assisted with the drafting of the report.
Dr Maciej Goniewicz (Associate Professor of Oncology) was involved in the preparation of the grant
proposal and the trial report.
Ms Qi Wu (Research Fellow) developed, updated and ran the health economics model.
Professor Hayden J McRobbie (Professor in Public Health Interventions) was a co-investigator. He
co-wrote the original grant application, co-designed the trial, co-wrote the statistical analysis plan, trained
staff, interpreted the trial findings and assisted with the drafting of the report.
Publication
Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A randomized trial of
e-cigarettes versus nicotine-replacement therapy. N Engl J Med 2019;380:629–37.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to
anonymised data may be granted following review.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
References
1. Sussan TE, Shahzad FG, Tabassum E, Cohen JE, Wise RA, Blaha MJ, et al. Electronic cigarette use
behaviors and motivations among smokers and non-smokers. BMC Public Health 2017;17:686.
https://doi.org/10.1186/s12889-017-4671-3
2. Public Health England. E-cigarettes and Heated Tobacco Products: Evidence Review. 2018. URL:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/
684963/Evidence_review_of_e-cigarettes_and_heated_tobacco_products_2018.pdf (accessed
5 January 2018).
3. Royal College of Physicians. Nicotine Without Smoke: Tobacco Harm Reduction. London: Royal
College of Physicians; 2016.
4. Hartmann-Boyce J, McRobbie H, Bullen C, Begh R, Stead LF, Hajek P. Electronic cigarettes for
smoking cessation. Cochrane Database Syst Rev 2016;9:CD010216. https://doi.org/10.1002/
14651858.CD010216.pub3
5. Action on Smoking and Health (ASH). Use of Electronic Cigarettes (Vapourisers) Among Adults in
Great Britain. London: ASH; 2016.
6. McEwen A, Hajek P, McRobbie H, West R. Manual of Smoking Cessation: A Guide For Counsellors
and Practitioners. Oxford: John Wiley and Sons; 2006.
7. Przulj D, McRobbie H, Hajek P. The effect of sensorimotor replacement on smoking cessation and
craving. Open Addict J 2012;5:41–50. https://doi.org/10.2174/1874941001205010041
8. West R, Beard E, Brown J. Trends in electronic cigarette use in England. Smoking Toolkit Study. 2018.
URL: www.smokinginengland.info/latest-statistics/ (accessed 13 May 2019).
9. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, Walker N. Electronic cigarettes
for smoking cessation: a randomised controlled trial. Lancet 2013;382:1629–37. https://doi.org/
10.1016/S0140-6736(13)61842-5
10. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, Polosa R. EffiCiency and
Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month
randomized control design study. PLOS ONE 2013;8:e66317. https://doi.org/10.1371/journal.pone.
0066317
11. Adriaens K, Van Gucht D, Declerck P, Baeyens F. Effectiveness of the electronic cigarette: an
eight-week Flemish study with six-month follow-up on smoking reduction, craving and experienced
benefits and complaints. Int J Environ Res Public Health 2014;11:11220–48. https://doi.org/10.3390/
ijerph111111220
12. Halpern SD, Harhay MO, Saulsgiver K, Brophy C, Troxel AB, Volpp KG. A pragmatic trial of
e-cigarettes, incentives, and drugs for smoking cessation. N Engl J Med 2018;378:2302–10.
https://doi.org/10.1056/NEJMsa1715757
13. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A randomized trial of
e-cigarettes versus nicotine-replacement therapy. N Engl J Med 2019;380:629–37. https://doi.org/
10.1056/NEJMoa1808779
14. Hajek P. Withdrawal-oriented therapy for smokers. Br J Addict 1989;84:591–8. https://doi.org/
10.1111/j.1360-0443.1989.tb03474.x
15. Hajek P, Etter JF, Benowitz N, Eissenberg T, McRobbie H. Electronic cigarettes: review of use,
content, safety, effects on smokers and potential for harm and benefit. Addiction
2014;109:1801–10. https://doi.org/10.1111/add.12659
DOI: 10.3310/hta23430 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 43
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hajek et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
69
16. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for
Cigarette Dependence. Nicotine Tob Res 2012;14:75–8. https://doi.org/10.1093/ntr/ntr137
17. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette
withdrawal. Psychopharmacology 2004;177:195–9. https://doi.org/10.1007/s00213-004-1923-6
18. Richardson G, Manca A. Calculation of quality adjusted life years in the published literature:
a review of methodology and transparency. Health Econ 2004;13:1203–10. https://doi.org/
10.1002/hec.901
19. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine
replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012;11:CD000146.
https://doi.org/10.1002/14651858.CD000146.pub4
20. Ferguson J, Bauld L, Chesterman J, Judge K. The English smoking treatment services: one-year
outcomes. Addiction 2005;100(Suppl. 2):59–69. https://doi.org/10.1111/j.1360-0443.2005.01028.x
21. Hajek P, Goniewicz ML, Phillips A, Myers Smith K, West O, McRobbie H. Nicotine intake from
electronic cigarettes on initial use and after 4 weeks of regular use. Nicotine Tob Res
2015;17:175–9. https://doi.org/10.1093/ntr/ntu153
22. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine
patch for smoking cessation: randomised trial with six year follow up. BMJ 1999;318:285–8.
https://doi.org/10.1136/bmj.318.7179.285
23. Polosa R, Caponnetto P, Maglia M, Morjaria JB, Russo C. Success rates with nicotine personal
vaporizers: a prospective 6-month pilot study of smokers not intending to quit. BMC Public Health
2014;14:1159. https://doi.org/10.1186/1471-2458-14-1159
24. Stapleton J. Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res
1998;7:187–203. https://doi.org/10.1177/096228029800700206
25. Bauld L, Hiscock R, Dobbie F, Aveyard P, Coleman T, Leonardi-Bee J, et al. English stop-smoking
services: one-year outcomes. Int J Environ Res Public Health 2016;13:E1175. https://doi.org/10.3390/
ijerph13121175
26. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a
common standard. Addiction 2005;100:299–303. https://doi.org/10.1111/j.1360-0443.2004.00995.x
27. Hajek P, Przulj D, Phillips A, Anderson R, McRobbie H. Nicotine delivery to users from cigarettes
and from different types of e-cigarettes. Psychopharmacology 2017;234:773–9. https://doi.org/
10.1007/s00213-016-4512-6
28. Hajek P, Jackson P, Belcher M. Long-term use of nicotine chewing gum. Occurrence, determinants,
and effect on weight gain. JAMA 1988;260:1593–6. https://doi.org/10.1001/jama.1988.
03410110101035
29. Dawkins L, Turner J, Roberts A, Soar K. ‘Vaping’ profiles and preferences: an online survey of
electronic cigarette users. Addiction 2013;108:1115–25. https://doi.org/10.1111/add.12150
30. Foulds J, Veldheer S, Yingst J, Hrabovsky S, Wilson SJ, Nichols TT, Eissenberg T. Development of a
questionnaire for assessing dependence on electronic cigarettes among a large sample of ex-smoking
e-cigarette users. Nicotine Tob Res 2015;17:186–92. https://doi.org/10.1093/ntr/ntu204
31. Shahab L, Goniewicz ML, Blount BC, Brown J, McNeill A, Alwis KU, et al. Nicotine, carcinogen, and
toxin exposure in long-term e-cigarette and nicotine replacement therapy users: a cross-sectional
study. Ann Intern Med 2017;166:390–400. https://doi.org/10.7326/M16-1107
32. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine
absorption from electronic cigarette use: comparison between first and new-generation devices.
Sci Rep 2014;4:4133. https://doi.org/10.1038/srep04133
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
33. Dawkins L, Kimber C, Puwanesarasa Y, Soar K. First- versus second-generation electronic
cigarettes: predictors of choice and effects on urge to smoke and withdrawal symptoms. Addiction
2015;110:669–77. https://doi.org/10.1111/add.12807
34. NHS Digital. Statistics on NHS Stop Smoking Services in England April 2017 to September 2017.
Leeds: NHS Digital; 2018.
35. Wu Q, Jiang D, Minor M, Chu HW. Electronic cigarette liquid increases inflammation and virus
infection in primary human airway epithelial cells. PLOS ONE 2014;9:e108342. https://doi.org/
10.1371/journal.pone.0108342
36. Sussan TE, Gajghate S, Thimmulappa RK, Ma J, Kim JH, Sudini K, et al. Exposure to electronic
cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. PLOS ONE
2015;10:e0116861. https://doi.org/10.1371/journal.pone.0116861
37. Miler J, Mayer B, Hajek P. Changes in the frequency of airway infections in smokers who switched
to vaping: results of an online survey. J Addict Res Ther 2016;7:290. https://doi.org/10.4172/
2155-6105.1000290
38. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric
safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without
psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet
2016;387:2507–20. https://doi.org/10.1016/S0140-6736(16)30272-0
39. The Preloading Investigators. Effects on abstinence of nicotine patch treatment prior to quitting
smoking: parallel, two arm, pragmatic randomised trial. BMJ 2018;361:k2164. https://doi.org/
10.1136/bmj.k2164
40. Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, et al. Randomized trial of nicotine
replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation:
effectiveness in clinical practice. Addiction 2013;108:2193–201. https://doi.org/10.1111/add.12304
41. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural
interventions for smoking cessation. Cochrane Database Syst Rev 2016;3:CD008286. https://doi.org/
10.1002/14651858.CD008286.pub3
42. Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch
more effective in helping smokers quit than varenicline alone? A randomised controlled trial.
BMC Med 2013;11:140. https://doi.org/10.1186/1741-7015-11-140
43. Hajek P. The development and testing of new nicotine replacement treatments: from ‘nicotine
replacement’ to ‘smoking replacement’. Addiction 2015;110(Suppl. 2):19–22. https://doi.org/
10.1111/add.12905
44. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology
Appraisal 2013. London: NICE; 2013.
45. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Canterbury: Personal Social Services
Research Unit, University of Kent, 2016.
46. Department of Health and Social Care (DHSC). Charges for NHS Prescriptions, Dental Charges,
Elastic Stockings and Tights, Wigs and Fabric Supports And Optical Voucher Values: Written
Statement – HLWS346. London: DHSC; 2015. URL: www.parliament.uk/business/publications/
written-questions-answers-statements/written-statement/Lords/2015-03-11/HLWS346/ (accessed
1 February 2018).
47. NHS Digital. Prescription Cost Analysis – England 2016. Leeds: NHS Digital; 2017.
48. NHS Business Services Authority. PD1 reports. 2017. URL: www.nhsbsa.nhs.uk/prescription-data/
dispensing-data/information-services-pd1-reports (accessed 10 October 2017).
DOI: 10.3310/hta23430 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 43
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hajek et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
71
49. The EuroQol Group. EQ-5D-5L User Guide: Basic Information on How to Use the EQ-5D-5L
Instrument (Version 2.0). Rotterdam; EuroQol Research Foundation; 2013. URL: www.euroqol.org/
fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-5L_v2.0_October_2013.pdf
(accessed 4 March 2015).
50. National Institute for Health and Care Excellence (NICE). Position Statement on Use of the EQ-5D-5L
Valuation Set. 2017. URL: www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-
technology-appraisal-guidance/eq5d5l_nice_position_statement.pdf (accessed 13 September 2017).
51. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for
the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15.
https://doi.org/10.1016/j.jval.2012.02.008
52. Rubin DB. Statistical matching using file concatenation with adjusted weights and multiple
imputations. J Bus Econ Stat 1986;4:87–94. https://doi.org/10.1080/07350015.1986.10509497
53. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance
for practice. Stat Med 2011;30:377–99. https://doi.org/10.1002/sim.4067
54. Efron B, Tibshirani R. An Introduction to the Bootstrap. London: Chapman & Hall; 1993.
https://doi.org/10.1007/978-1-4899-4541-9
55. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an
example from a randomized trial. Stat Med 1996;15:1447–58. https://doi.org/10.1002/(SICI)1097-
0258(19960715)15:13<1447::AID-SIM267>3.0.CO;2-V
56. Willan AR, O’Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller’s
theorem. Health Econ 1996;5:297–305. https://doi.org/10.1002/(SICI)1099-1050(199607)5:4
<297::AID-HEC216>3.0.CO;2-T
57. Severens JL, De Boo TM, Konst EM. Uncertainty of incremental cost-effectiveness ratios. A
comparison of Fieller and bootstrap confidence intervals. Int J Technol Assess Health Care
1999;15:608–14.
58. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness
acceptability curves. Health Econ 2001;10:779–87. https://doi.org/10.1002/hec.635
59. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions
to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275–83. https://doi.org/
10.1136/bmj.313.7052.275
60. Drummond M, Sculpher M, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic
Evaluation of Health Care Programmes. 3rd edn. Oxford: Oxford University Press; 2005.
61. Coyle D, Davies L, Drummond MF. Trials and tribulations. Emerging issues in designing economic
evaluations alongside clinical trials. Int J Technol Assess Health Care 1998;14:135–44. https://doi.org/
10.1017/S0266462300010588
62. Petrou S, Gray A. Economic evaluation alongside randomised controlled trials: design, conduct,
analysis, and reporting. BMJ 2011;342:d1548. https://doi.org/10.1136/bmj.d1548
63. International Agency for Research on Cancer (IARC). IARC Monographs on the Evaluation of
Carcinogenic Risk to Humans. Volume 83: Tobacco Smoke and Involuntary Smoking. Lyon: World
Health Organization International Agency for Research on Cancer; 2004. URL: http://monographs.
iarc.fr/ENG/Monographs/vol83/mono83.pdf (accessed 15 December 2017).
64. US Department of Health & Human Services. The Health Consequences of Smoking – 50 Years of
Progress: A Report of the Surgeon General, 2014. Washington, DC: US Department of Health &
Human Services; 2014. URL: www.surgeongeneral.gov/library/reports/50-years-of-progress/
full-report.pdf (accessed 20 February 2018).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
65. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on
male British doctors. BMJ 2004;328:1519. https://doi.org/10.1136/bmj.38142.554479.AE
66. Wu Q, Parrott S, Godfrey C, Gilbert H, Nazareth I, Leurent B, et al. Cost-effectiveness of
computer-tailored smoking cessation advice in primary care: a randomized trial (ESCAPE).
Nicotine Tob Res 2014;16:270–8. https://doi.org/10.1093/ntr/ntt136
67. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford:
Oxford University Press; 2006.
68. Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: a meta-analysis.
Addict Behav 2008;33:1516–20. https://doi.org/10.1016/j.addbeh.2008.05.012
69. US Department of Health & Human Services. The Health Benefits of Smoking Cessation: A Report
of the US Surgeon General. Washington, DC: US Department of Health & Human Services; 1990.
70. Hawkins J, Hollingworth W, Campbell R. Long-term smoking relapse: a study using the British
household panel survey. Nicotine Tob Res 2010; 12(12):1228–35. https://doi.org/10.1093/ntr/
ntq175
71. Office for National Statistics (ONS). Deaths registered in England and Wales: 2016. 2017. URL:
www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/
deathsregistrationsummarytables/2016 (accessed 23 May 2019).
72. Vogl M, Wenig CM, Leidl R, Pokhrel S. Smoking and health-related quality of life in English general
population: implications for economic evaluations. BMC Public Health 2012;12:203. https://doi.org/
10.1186/1471-2458-12-203
73. National Centre for Social Research and University College London. Department of Epidemiology
and Public Health, Health Survey for England. UK Data Archive; 2006.
74. World Health Organization (WHO). Economics of Tobacco Toolkit: Assessment of the Economic
Costs of Smoking. Geneva: WHO; 2011.
75. NHS Digital. Hospital Admitted Patient Care Activity, 2016–17. London: NHS Digital; 2017.
76. Royal College of Physicians. Hiding in Plain Sight: Treating Tobacco Dependency in the NHS.
London: Royal College of Physicians; 2018.
77. Department of Health and Social Care (DHSC). NHS Reference Costs 2015 to 2016. London:
DHSC; 2016.
78. Health and Social Care Information Centre (HSCIC). HRG4+ 2015/16 Reference Costs Code to
Group Workbook. Leeds: HSCIC; 2016.
79. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability
curves: an example using data from a trial of management strategies for atrial fibrillation.
BMC Health Serv Res 2006;6:52. https://doi.org/10.1186/1472-6963-6-52
80. National Institute for Health and Care Excellence (NICE). Smoking Cessation Services Costing
Report – Implementing NICE Guidance. London: NICE; 2008.
81. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. Canterbury: Personal Social Services
Research Unit, University of Kent; 2015.
DOI: 10.3310/hta23430 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 43
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Hajek et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
73
Appendix 1 Supplementary tables
TABLE 32 Summary of protocol amendments
Approved
versiona Date Summary
3.0 8 April 2015 Change of site address and principal investigator at QMUL. Clarifications to statistics
4.0 29 May 2015 Change of chief investigator
5.0 11 May 2016 Change to advertising strategies, change to storage of data and clarification regarding
modes of contact used for participants who miss appointments/follow-up calls
a Versions 1.0 and 2.0 were drafts prior to ethics approval.
TABLE 33 Trial committee members
Name Role Committee
Professor Ian Roberts Chairperson (independent) TSC
Professor Sarah Lewis Member (independent) TSC
Professor Linda Bauld Member (independent) TSC
Professor Michael Ussher Member (independent) TSC
Mr Darush Attar-Zadeh Member (independent) TSC
Mr Brian Eastwood Lay member (independent) TSC
Mr Benjamin Roberts Lay member TSC
Professor Tim Peto Chairperson (independent) DMEC
Dr Angela Crook Member (independent) DMEC
Dr Lion Shahab Member (independent) DMEC
Mrs Anna Phillips-Waller Study Manager TMG
Professor Peter Hajek Chief Investigator TMG
Dr Dunja Przulj Researcher TMG
Mr Benoit Aigret Head of Barts CTU TMG
Mr Richard Ostler Barts CTU programmer TMG
TMG, Trial Management Group.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
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TABLE 34 Serious adverse events listed by study arm
E-cigarette arm NRT arm
l Death from acute myocardial infarction
l Femoral fracture
l Colon cancer
l Ovarian cyst ruptured
l Renal stone removal
l Depression
l Fibromyalgia
l Infective exacerbation of chronic obstructive airways disease (×2)
l Tonsillar bleeding
l Intervertebral disc disorder
l Ovarian cystectomy
l Pneumonia (×2)
l Cholecystitis
l Ear infection, bacterial
l Knee surgery, NOS
l Hospitalisation, reason not disclosed
l Urinary tract infection bacterial
l Allergic reaction
l Eye infection intraocular
l Hospitalisation, reason not disclosed
l Acute myocardial infarction
l Suicidal ideation
l Abdominal sepsis
l Malignant neoplasm of oropharynx, NOS
l Asthmatic attack
l Death from spinal cord injury
l Pulmonary and ovarian mass
l Diverticulitis
l Ovarian abscess
l Transient ischaemic attack
l Nephrolithiasis
l Bacterial sepsis
l Asthmatic attack
l Acute myocardial infarction
l Coronary artery bypass
l Diverticulitis
l Intervertebral disc disorders
l Neoplasm of unspecified nature
l Cervical vertebral fracture
l Tendinitis, NOS
l Acute pancreatitis unspecified
l Hernia of abdominal cavity
l Pyelonephritis
l Other knee injury
l Acute pancreatitis unspecified
l Headaches
l Cholecystitis acute
NOS, not otherwise specified.
From Hajek P, et al.13 A randomized trial of e-cigarettes versus nicotine-replacement therapy. The New England Journal of
Medicine Vol. 380, pp. 629–37. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission.
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TABLE 35 Unit costs of services and pharmacotherapies (2015/16 prices)
Service Unit cost (£) Source
Smoking cessation help
GP 36 per session Curtis and Burns45
NHS SSS 17 per session Curtis and Burns45 and NICE80
NHS Smoking Helpline service 7 per call Curtis and Burns45 and Wu et al.66
Pharmacotherapies (including dispensing fee)
Patch 27 per item NHS Digital47 and NHS Business Services Authority48
Gum 15 per item NHS Digital47 and NHS Business Services Authority48
Microtab 19 per item NHS Digital47 and NHS Business Services Authority48
Inhaler 36 per item NHS Digital47 and NHS Business Services Authority48
Lozenge 17 per item NHS Digital47 and NHS Business Services Authority48
Spray 30 per item NHS Digital47 and NHS Business Services Authority48
Mouth strip 17 per item NHS Digital47 and NHS Business Services Authority48
Varenicline 37 per item NHS Digital47 and NHS Business Services Authority48
Bupropion 40 per item NHS Digital47 and NHS Business Services Authority48
Health-care service use
A&E 162 per attendance NHS Reference Costs 2015 to 201677
Hospital outpatient 135 per appointment NHS Reference Costs 2015 to 201677
Hospital inpatient 606 per night NHS Reference Costs 2015 to 201677
Day case 733 per episode NHS Reference Costs 2015 to 201677
Emergency ambulance 96 per use NHS Reference Costs 2015 to 201677
GP (in office) 31 per consultation Curtis and Burns45
Practice nurse (in office) 9 per visit Curtis and Burns45,81
GP (home visit) 56 per consultation Curtis and Burns45,81
Practice nurse (home visit) 17 per visit Curtis and Burns45,81
Prescription (NIC + dispensing) 22 per prescription NHS Business Services Authority48
A&E, accident and emergency; NIC, net ingredient cost.
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TABLE 36 Model parameters identified and extracted from literature and secondary data sources
Parameters Value (SE) Source
Annual probability of relapse (%)
≤ 10 years 10.00 (3.06) Hughes et al.,68 US HHS,69 Hawkins et al.70
> 10 years 0 (0) Hughes et al.,68 US HHS,69 Hawkins et al.70
Mortality (%)
Men
Continuing smokers, age (years)
35–44 0.24 (0.40) Doll et al.,65 ONS71
45–54 0.80 (0.40) Doll et al.,65 ONS71
55–64 1.94 (0.52) Doll et al.,65 ONS71
65–74 5.15 (0.82) Doll et al.,65 ONS71
≥ 75 25.36 (2.04) Doll et al.,65 ONS71
Ex-smokers, age (years)
35–44 0.18 (0.35) Doll et al.,65 ONS71
45–54 0.51 (0.73) Doll et al.,65 ONS71
55–64 1.24 (0.58) Doll et al.,65 ONS71
65–74 3.08 (0.59) Doll et al.,65 ONS71
≥ 75 15.12 (1.14) Doll et al.,65 ONS71
Women
Continuing smokers, age (years)
35–44 0.14 (0.31) Doll et al.,65 ONS71
45–54 0.53 (0.33) Doll et al.,65 ONS71
55–64 1.30 (0.43) Doll et al.,65 ONS71
65–74 3.45 (0.68) Doll et al.,65 ONS71
≥ 75 20.79 (1.90) Doll et al.,65 ONS71
Ex-smokers, age (years)
35–44 0.11 (0.27) Doll et al.,65 ONS71
45–54 0.34 (0.59) Doll et al.,65 ONS71
55–64 0.83 (0.48) Doll et al.,65 ONS71
65–74 2.06 (0.49) Doll et al.,65 ONS71
≥ 75 12.40 (1.05) Doll et al.,65 ONS71
Annual smoking-related healthcare costs after the first year (£)
Men
Continuing smokers, age (years)
35–44 54.48 (0) NHS Digital,75 DHSC,77 HSCIC78
45–54 54.48 (0) NHS Digital,75 DHSC,77 HSCIC78
55–64 181.97 (0) NHS Digital,75 DHSC,77 HSCIC78
65–74 315.75 (0) NHS Digital,75 DHSC,77 HSCIC78
≥ 75 535.22 (0) NHS Digital,75 DHSC,77 HSCIC78
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TABLE 36 Model parameters identified and extracted from literature and secondary data sources (continued )
Parameters Value (SE) Source
Ex-smokers, age (years)
35–44 16.57 (0) NHS Digital,75 DHSC,77 HSCIC78
45–54 16.57 (0) NHS Digital,75 DHSC,77 HSCIC78
55–64 64.99 (0) NHS Digital,75 DHSC,77 HSCIC78
65–74 83.82 (0) NHS Digital,75 DHSC,77 HSCIC78
≥ 75 105.36 (0) NHS Digital,75 DHSC,77 HSCIC78
Women
Continuing smokers, age (years)
35–44 41.31 (0) NHS Digital,75 DHSC,77 HSCIC78
45–54 41.31 (0) NHS Digital,75 DHSC,77 HSCIC78
55–64 119.83 (0) NHS Digital,75 DHSC,77 HSCIC78
65–74 249.03 (0) NHS Digital,75 DHSC,77 HSCIC78
≥ 75 470.69 (0) NHS Digital,75 DHSC,77 HSCIC78
Ex-smokers, age (years)
35–44 10.72 (0) NHS Digital,75 DHSC,77 HSCIC78
45–54 10.72 (0) NHS Digital,75 DHSC,77 HSCIC78
55–64 40.95 (0) NHS Digital,75 DHSC,77 HSCIC78
65–74 71.25 (0) NHS Digital,75 DHSC,77 HSCIC78
≥ 75 103.18 (0) NHS Digital,75 DHSC,77 HSCIC78
Annual QALY gain after the first year
Men
Continuing smokers, age (years)
35–44 0.889 (0.007) Vogl et al.72
45–54 0.841 (0.007) Vogl et al.72
55–64 0.780 (0.008) Vogl et al.72
65–74 0.756 (0.008) Vogl et al.72
≥ 75 0.710 (0.009) Vogl et al.72
Ex-smokers, age (years)
35–44 0.889 (0.007) Vogl et al.72
45–54 0.841 (0.007) Vogl et al.72
55–64 0.780 (0.008) Vogl et al.72
65–74 0.756 (0.008) Vogl et al.72
≥ 75 0.710 (0.009) Vogl et al.72
Women
Continuing smokers, age (years)
35–44 0.870 (0.007) Vogl et al.72
45–54 0.830 (0.007) Vogl et al.72
55–64 0.763 (0.008) Vogl et al.72
65–74 0.751 (0.008) Vogl et al.72
≥ 75 0.676 (0.009) Vogl et al.72
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TABLE 36 Model parameters identified and extracted from literature and secondary data sources (continued )
Parameters Value (SE) Source
Ex-smokers, age (years)
35–44 0.889 (0.004) Vogl et al.72
45–54 0.850 (0.005) Vogl et al.72
55–64 0.784 (0.005) Vogl et al.72
65–74 0.773 (0.006) Vogl et al.72
≥ 75 0.700 (0.007) Vogl et al.72
Annual discount rate (%)
Cost discount rate 3.5 NICE44
Outcome discount rate 3.5 NICE44
DHSC, Department of Health and Social Care; HHS, Department of Health & Human Services; HSCIC, Health and Social
Care Information Centre; ONS, Office for National Statistics.
TABLE 37 Unit costs of selected NRT products provided by the trial
NRT product Cost per item+ fee (£)
24-hour patch
21 mg 25
14 mg 25
7 mg 25
16-hour patch
25 mg 24
15 mg 26
10 mg 26
Microtab (2 mg) 17
Mouth strip (2.5 mg) 15
Gum
4mg 15
2 mg 12
Lozenge
4 mg 15
2 mg 15
Nasal spray 41
Minis
4 mg 17
1.5 mg 15
Inhalator 33
Mouth spray 26
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TABLE 38 Use of health-care services among responders at each follow-up point, by arm
Health-care
service
Trial arm, mean (SD)
NRT E-cigarette
Baseline
(n= 447)
6 months
(n= 270)
12 months
(n= 283)
Baseline
(n= 439)
6 months
(n= 306)
12 months
(n= 316)
A&E 0.19 (0.52) 0.11 (0.47) 0.10 (0.32) 0.24 (0.80) 0.11 (0.38) 0.10 (0.34)
Outpatient 1.04 (5.18) 0.85 (3.92) 0.68 (2.55) 0.73 (2.23) 0.85 (3.71) 0.68 (3.07)
Inpatient (nights) 0.30 (2.87) 0.22 (1.57) 0.32 (2.80) 0.23 (1.78) 0.17 (1.61) 0.50 (3.58)
Day case 0.16 (0.77) 0.06 (0.24) 0.14 (1.45) 0.13 (0.48) 0.13 (0.97) 0.08 (0.35)
Emergency
ambulance
0.04 (0.22) 0.03 (0.38) 0.04 (0.20) 0.06 (0.31) 0.01 (0.08) 0.03 (0.16)
GP (in office) 2.05 (3.17) 1.40 (2.98) 1.37 (2.22) 2.04 (3.69) 1.41 (2.58) 1.52 (2.95)
Practice nurse
(in office)
0.56 (1.84) 0.51 (2.02) 0.31 (0.69) 0.72 (2.04) 0.49 (1.88) 0.37 (0.87)
GP (home visit) 0.01 (0.08) – 0.00 (0.06) 0.00 (0.05) 0.02 (0.15) 0.02 (0.23)
Practice nurse
(home visit)
0.01 (0.19) 0.01 (0.18) 0.17 (2.85) – 0.01 (0.08) 0.01 (0.11)
Prescription 3.13 (6.39) 2.74 (5.85) 2.98 (4.78) 2.92 (5.55) 2.55 (6.02) 2.53 (4.43)
A&E, accident and emergency.
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